СРЕДСТВО ХРОНОБИОЛОГИЧЕСКОЙ КОРРЕКЦИИ (ВАРИАНТЫ) И СПОСОБ ХРОНОБИОЛОГИЧЕСКОЙ КОРРЕКЦИИ

Изобретение относится к медицине и может быть использовано для коррекции десинхроноза функций различных органов и систем организма человека, вызванного профессиональными и техногенными факторами. Предложены варианты средства хронобиологической коррекции с учетом органотропности проявления десинхроноза. Все варианты заявляемого средства хронобиологической коррекции состоят из двух комплексов. Утренний комплекс включает растительные компоненты мягкого тонизирующего и биостимулирующего действия и комплекс растительных адаптогенов, вечерний комплекс включает растительные компоненты мягкого успокаивающего и седативного действия и стимулирующие восстановление клеточных ресурсов. Кроме того, утренний и вечерний комплексы включают витамины, минеральные вещества, антиоксиданты и специфические биологически активные вещества, направленные на коррекцию специфических органных или системных нарушений, развивающихся вследствие хронического десинхроноза. Предложен способ хронобиологической коррекции с ...

СПОСОБ ПОЛУЧЕНИЯ ФУКОЗЫ И ФУКОЗОСОДЕРЖАЩИХ ГИДРОЛИЗАТОВ ИЗ БИОМАССЫ БУРЫХ ВОДОРОСЛЕЙ

Изобретение относится к фармацевтической промышленности, а именно к способу получения фукозы и фукозосодержащих гидролизатов из бурых водорослей. Способ получения фукозы и фукозосодержащих гидролизатов из бурых водорослей заключается в том, что измельченную бурую водоросль рода Fucus заливают этанолом, экстрагируют, экстракт отделяют, затем обработанную водоросль экстрагируют раствором соляной кислоты, экстракт концентрируют, нейтрализуют, упаривают и получают концентрат, содержащий полисахарид-1, из которого этанолом осаждают фукоидан (F1), после выделения F1 обработанную водоросль дважды экстрагируют горячей водой, экстракты объединяют и концентрируют, полученный концентрат упаривают и получают полисахарид-2, доводят pH концентрата до значения 2,0-2,5, выпавший осадок полиманнуроновой кислоты отделяют центрифугированием, супернатант нейтрализуют и осаждают этанолом фукоидан (F2), осадок промывают этанолом и высушивают, обе фракции фукоидана F1 и F2 соединяют и растворяют в дистиллированной ...

ОРАЛЬНЫЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ МОРСКИЕ ВОДОРОСЛИ, ДЛЯ СНИЖЕНИЯ ЗУБНОГО НАЛЕТА И КОНКРЕМЕНТА И СПОСОБПРОФИЛАКТИКИ И/ИЛИ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ ЗУБНОГО НАЛЕТА И КОНКРЕМЕНТА

Изобретение относится к области стоматологии и касается препарата для уменьшения зубного налета и/или конкремента. Для этого используют морскую водоросль Ascophyllum sp., которая имеет определенный химический состав. Применяют препарат в виде порошка, суспензии, таблетки, капсул. Способ профилактики и/или терапевтического лечения зубного налета и/или конкремента включает введение субъекту 250 мг - 1 г морской водоросли в составе препарата 2-4 таблетки в день. Препарат обеспечивает устранение бактериального налета и конкремента. 2 н. и 3 з.п. ф-лы, 3 табл.

ЧАЙ "НЕПОЛНИТА-ФИТО" ИЗ ЛЕКАРСТВЕННЫХ РАСТЕНИЙ ДЛЯ СНИЖЕНИЯ ИЗБЫТОЧНОГО ВЕСА

Изобретение относится к области создания средства в форме фиточая для лечения и профилактики ожирения. Фиточай для снижения веса содержит листья сенны, плоды шиповника, листья крапивы, листья толокнянки, корневища и корни девясила, слоевища ламинарии и траву череды при следующем содержании компонентов, мас.%: плоды шиповника 25-35, листья крапивы 5-15, листья толокнянки 5-15, корневища и корни девясила 5-15, листья сенны 15-25, слоевища ламинарии 5-15, трава череды остальное. Фиточай обладает умеренным диуретическим и послабляющим действием, при этом пациент полностью сохраняет социальную и трудовую активность в период лечения. Кроме того, фиточай можно применять пожилым пациентам, а также больным с наличием сопутствующей соматической патологии. 1 табл.

ЛЕКАРСТВЕННОЕ СРЕДСТВО "РАСТОСПИР", ОБЛАДАЮЩЕЕ ГЕПАТОПРОТЕКТОРНЫМ, ИММУНОМОДУЛИРУЮЩИМ И АНТИОКСИДАНТНЫМ ДЕЙСТВИЕМ, И БИОЛОГИЧЕСКИ АКТИВНАЯ ДОБАВКА НА ЕГО ОСНОВЕ

Изобретение относится к медицине, а именно к получению лекарственных средств из растительного сырья. Средство и биологически активная добавка содержат обезжиренные плоды расторопши пятнистой и в них дополнительно включена биомасса микроводоросли спируллины, взятые в определенном соотношении. Средство позволяет получить на 20-30% более выраженный гепатопротекторный аффект по сравнению с ближайшим аналогом за счет оптимального сочетания гепатопротекторных, иммунокоррегирующих и антиоксидантных свойств субстанций и их синергизма. 2 с.п.ф-лы.

БИОЛОГИЧЕСКИ АКТИВНАЯ ДОБАВКА К ПИЩЕ "МИГИКАЛЬГИН"

Изобретение относится к биологически активным добавкам к пище, полученным путем переработки водных объектов промысла, например водорослей и моллюсков. Биологически активная добавка к пище содержит альгинат кальция и белковый гидролизат из мяса моллюсков в количестве, мас.ч.: альгинат кальция 210,5-280,0, белковый гидролизат из мяса моллюсков 190-240,0. Изобретение позволяет получить продукт с полифункциональными свойствами на основе энтеросорбента и источника кальция и азотсодержащих компонентов в максимально доступной для организма форме, а также с повышенной биологической активностью. 1 з.п. ф-лы, 4 табл.

СПОСОБ ПОЛУЧЕНИЯ СЕЛЕНСОДЕРЖАЩЕГО ПРЕПАРАТА БИОМАССЫ СПИРУЛИНЫ

Изобретение относится к области биотехнологии, микробиологической и фармакологической промышленности. Питательную среду Заруха для культивации спирулины готовят по частям. В первую часть раствора, содержащую только NaHCO3, К2НРО4•3Н2О и Na2CO3 при рН<10, добавляют селенсодержащий препарат - селенистую кислоту (Н2SeO3). Затем первый раствор смешивают со вторым раствором, содержащим все остальные компоненты среды Заруха: NaNO3, K2SO4, NaCl, MgSO4, CaCl2•2H2O, FeSO4•7H2O, Na2EDTA, а также микроэлементы: H3BO3, MnCl2 •4H2O, ZnSO4•7H2O, CuSO4•5H2O, MoO3, NH4VO3, K2Cr2(SO4 )2•12H2O, NiSO4•7H2O, Na2WO4•2H2O, Ti2(SO4)3, Co(NO3)2•6H2O. Изобретение позволяет повысить биологическую ценность продукта. 1 з.п.ф-лы, 3 ил.

ЭКСТРАКТЫ Aphanizomenon Flos Aquae И ПИТАТЕЛЬНЫЕ, КОСМЕТИЧЕСКИЕ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ

Изобретение относится к фармацевтической и косметической промышленности, в частности к средству, обладающему антиоксидантными, противовоспалительными и противоопухолевыми свойствами. Водорастворимая фракция кламатских микроводорослей Aphanizomenon Flos Aquae Aquae Ralfs ex Born. &Flah. Var. flos aquae (водорослей AFA), обладающая антиоксидантными, противовоспалительными и противоопухолевыми свойствами, включающая фикобилисому, содержащую фикоцианин/фикоэритроцианин (С-РС/РЕС), фиковиолобилин (PVB), фитохром AFA, микоспоринподобные аминокислоты, хлорофилл и каротины. Выделенный биологически активный компонент водорастворимой фракции кламатских микроводорослей AFA. Композиция, содержащая водорастворимую фракцию или выделенный компонент, или их смесь. Применение водорастворимой фракции кламатских водорослей или их выделенного компонента (варианты). Вышеописанная фракция или биологически активный компонент обладают эффективными антиоксидантными, противовоспалительными и противоопухолевыми свойствами ...

СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ОСТЕОАРТРОЗОМ С ПРЕИМУЩЕСТВЕННЫМ ПОРАЖЕНИЕМ КОЛЕННЫХ И ГОЛЕНОСТОПНЫХ СУСТАВОВ

Изобретение относится к медицине, а именно к физиотерапии. Способ включает проведение щадящего двигательного режима, диетического питания, морских купаний. При этом на область пораженных суставов воздействуют дарсонвализацией от аппарата «Искра-1». Воздействие осуществляют переменным током частотой 110 Гц, модулированным в серии колоколообразной формы, длительностью 100 мкс, следующие с частотой 50 Гц, при напряжении на электроде 25-30 кВ, при средней мощности и ощущении пациентом умеренного тепла под электродом. Воздействуют контактно, лабильно, в течение 10-15 минут. Через 15-20 минут после указанной процедуры на область этих же суставов осуществляют наложение аппликации из морских водорослей анапского региона. Толщина аппликации 5-6 см. Температуру аппликаций снижают постепенно. При первых трех процедурах она составляет 40-42°С, при 4-5 процедурах 38-40°С, при 6-7 процедурах 36-38°С, а при 8-10 процедурах 34-36°С. Время воздействия 20-25 минут. На курс 10 процедур, проводимых через 1 ...

СПОСОБ ПОЛУЧЕНИЯ ПЕКТИНА ИЗ МОРСКИХ ТРАВ.

Изобретение относится к химико-фармацевтической промышленности и касается способа получения пектина из морских трав. 3адача изобретения заключается в создании способа получения пектина из морских трав по безотходной и эколокически чистой технологии с выделением пектинов, обладающих биологической активностью в отношении иммунной системы. Способ включает измельчение сухой морской травы из семейства Zosterae, приготовление суспензии, ее обработку ультразвуком при постоянной температуре и разделение на фракции хроматографией на сефарозе или импрегнированном силикагеле. Технический результат заключается в разработке способа получения пектинов из морских трав ...

СРЕДСТВО, ПОВЫШАЮЩЕЕ ЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА

Изобретение относится к медицине, а именно - к фтизиатрии. Предложено применять лечебно-пищевую добавку из ламинарии "Фитолон" в комплексе с известными противотуберкулезными средствами изониазидом и рифампицином. Препарат угнетает жизнеспособность микобактерий туберкулеза, проявляет синергическое взаимодействие с изониазидом и рифампицином, ускоряет регрессию патологического процесса за счет экссудативного компонента воспаления, а также благоприятно влияет на иммунный статус. 4 табл.

СОДЕРЖАЩАЯ КОМБИНАЦИЮ ЦЕОЛИТ/ВОДОРОСЛИ ИЛИ ЦЕОЛИТ/ЭМУЛЬСИЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДА

Изобретение относится к химико-фармацевтической промышленности и представляет собой фармацевтическую композицию для лечения или профилактики СПИДа в пригодной для орального применения выпускной форме, содержащую: от 1 до 99% масс., по меньшей мере одного цеолита, монтмориллонита или их смеси в качестве компонента F; от 1 до 99% масс., по меньшей мере одной не подвергнутой обработке или высушенной сине-зеленой водоросли в качестве компонента G; от 0 до 50% масс., обычных фармацевтических вспомогательных веществ и добавок в качестве компонента Н; причем общее количество компонентов F, G и при необходимости Н составляет 100% масс., и причем массовое отношение компонентов F и G в расчете на сухую массу находится в интервале от 0,2:1 до 5:1. Изобретение обеспечивает создание композиции для лечения или профилактики СПИДа, включающую комбинацию цеолитов с водорослевыми препаратами. 2 н. и 9 з.п. ф-лы, 1 пр.

СПОСОБ ЛЕЧЕНИЯ НЕФРОПАТИЙ В ЭКОЛОГИЧЕСКИ НЕБЛАГОПРИЯТНЫХ УСЛОВИЯХ У ДЕТЕЙ

Изобретение относится к медицине, а именно к урологии, и может быть использовано в терапии нефропатий у детей из экологически неблагоприятных регионов с высоким содержанием тяжелых металлов в окружающей среде. Для этого дополнительно вводят 4% альгинат натрия (вытяжка из бурых морских водорослей) по 5 мл на 1 м поверхности тела 3 раза в день 3 недели. В результате снимается интоксикация, выводятся депонированные в тканях тяжелые металлы, нормализуются обменные процессы и устраняется мочевой синдром. 3 табл.

КОМПЛЕКС И СПОСОБ РЕАБИЛИТАЦИИ БОЛЬНЫХ С СОЧЕТАННОЙ ВЕРТЕБРАЛЬНОЙ И СЕРДЕЧНО-СОСУДИСТОЙ ПАТОЛОГИЕЙ

Изобретение касается лекарственных средств для реабилитации больных с сочетанной вертебральной и сердечно-сосудистой патологией. Предложена группа изобретений. Комплекс для реабилитации больных с сочетанной вертебральной и сердечно-сосудистой патологией включает гомеопатический препарат “Кралонин” и биологически активную добавку “Сплат”. Способ реабилитации больных с сочетанной вертебральной и сердечно-сосудистой патологией заключается в том, что пациенту вводят ежедневно меняющуюся по экспоненциальному режиму дозу гомеопатического препарата “Кралонин”, далее биологически активную добавку “Сплат” и осуществляют мягкую тракционную терапию по общепринятой методике. Предложенные терапевтические средства позволяют осуществить целенаправленное воздействие на различные патогенетические механизмы сочетанной вертебральной и сердечно-сосудистой патологии. 2 н.п. ф-лы, 2 табл.

СПОСОБ ЛЕЧЕНИЯ АТЕРОСКЛЕРОЗА

Изобретение относится к медицине, в частности к терапии, рефлексотерапии. Способ включает проведение комбинированной внутривенной и наружной лазеротерапии в сочетании с комплексным медикаментозным воздействием на организм. Дополнительно больному проводят мониторную очистку кишечника, ежедневно, курсом 6-8 процедур. Наружную лазеротерапию проводят на корпоральные и аурикулярные точки. Медикаментозная терапия включает введение внутримышечно иммуномодуляторов Т-активина в дозе 100 мкг в день и Галавита в дозе 100 мг в день, курсом лечения 10-20 процедур. Осуществляют прием Ацикловира в дозе 1 г в день курсом лечения 14 дней. Прием Эйконола в капсулах в дозе 6-9 в день, медных производных хлорофилла в дозе 0,1 г в день и пищевой добавки Альгинат натрия в дозе 4 г в день проводят в течение всего курса лечения. Внутривенную и наружную лазеротерапию проводят курсом 8-10 процедур. Способ обеспечивает нормализацию клеточного и гуморального иммунитета, повышает длительность последствия проводимой ...

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ РЕГУЛИРОВАНИЯ САХАРА И ЖИРА В КРОВИ, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ

Изобретение относится к химико-фармацевтической промышленности, а именно к созданию фармацевтической композиции для регулирования сахара и жира в крови, к способу получения фармацевтической композиции, к ее применению. Фармацевтическая композиция содержит следующие китайские лекарственные растения или их экстракты в массовых частях: 5-17 плодов бирючины блестящей (Ligustri lucidui), 3-12 корня монгольского астрагала {Radix Astragali Mongolici), 1-5 корневища коптиса китайского (Rhizoma Coptidis), 1-5 семян личи китайской (Semen Litchi), с возможным добавлением 1-6 ламинарии (Thallus Laminariae Japonicae) и 1-6 корневища куркумы длинной (Rhizoma Curcumae Longae). Фармацевтическую композицию настоящего изобретения можно применять для лечения сахарного диабета. 5 н. и 5 з.п. ф-лы, 27 табл.

СПОСОБ ЛЕЧЕНИЯ ЦЕЛЛЮЛИТА

Изобретение относится к области медицины и косметологии и касается методов лечения целлюлита. Предложен способ лечения целлюлита, характеризующийся тем, что в проблемные участки кожи втирают до полного всасывания стимулирующий крем, содержащий в качестве активных начал порошок сине-зеленых водорослей и пресноводной губки, морской фитопланктон, экстракты ананаса, папайи и киви, экстракты конского каштана и плюща, затем на 2-3 мин наносят очищающий ферментный гель, содержащий в качестве активных начал ферментные комплексы киви, ананаса и папайи, экстракт зеленого чая, экстракт сине-зеленых водорослей, после удаления его избытка наносят и выдерживают до полного впитывания препарат липолитического действия, содержащий в качестве активных начал липофирм, экстракт бурых морских водорослей, кофеин, карнитин, масло чайного дерева, экстракты арники и конского каштана, сразу после этого массирующими движениями наносят разогревающий гель, содержащий в качестве активных начал морские сублимированные ...

ПРОФИЛАКТИЧЕСКОЕ И ОБЩЕУКРЕПЛЯЮЩЕЕ СРЕДСТВО ШИРОКОГО СПЕКТРА ДЕЙСТВИЯ

Изобретение относится к медицине, а именно к профилактическому и общеукрепляющему средству. Изобретение заключается в том, что средство содержит спирулину, аскорбиновую кислоту и мед и может быть использовано в виде таблеток или твердых желатиновых капсул. Изобретение обеспечивает улучшение витаминного комплекса, входящего в спирулину, а также позволяет устранить специфический запах микроводоросли. 1 табл.

СПОСОБ ЛЕЧЕНИЯ КОСТНО-МОЗГОВОЙ ФОРМЫ ОСТРОЙ ЛУЧЕВОЙ БОЛЕЗНИ

Изобретение относится к медицине и может быть использовано в радиобиологических экспериментальных исследованиях на млекопитающих для изучения механизма действия радиации на организм и в практическом здравоохранения для лечения костно-мозговой формы острой лучевой болезни. Предложено в качестве лечебного средства использовать 1 ___→ 3; 1 ___→ 6 - β -D-глюкан - транслам. Препарат не вызывает побочных явлений, имеет низкую токсичность. 5 табл.

СПОСОБ СНИЖЕНИЯ ВЕСА

Изобретение относится к медицине, а именно к профилактической медицине, и может быть использовано как способ снижения веса. Вместе с приемом пищи осуществляют прием пищевой добавки, состоящей из агар-агара и включающей экстракт стевии и пиколинат хрома. При первом приеме пищевой добавки однократно вводится раствор, содержащий пируват натрия, аскорбиновую кислоту и L-карнитин, на глубину до 20 мм путем внутримышечной инъекции, либо в нижнюю часть живота в проекции биологически активной точки, расположенной на расстоянии 50 мм вниз от пупка по срединной линии живота с дозировкой инъекции 4 мл, либо в проекции биологически активных точек, находящихся на расстоянии 70 мм вправо и влево от 7 шейного позвонка. Способ обеспечивает снижение и стабилизацию веса человека путем ускорения липолиза и метаболизма, уменьшение чувства голода и повышение чувства насыщения при обеспечении необходимой питательной ценности потребляемой пищи за счет приема пищевой добавки в комплексе с однократным введением ...

Способ получения полисахаридов из шрота (отходов переработки) бурых водорослей

Изобретение относится к области химико-фармацевтической и пищевой промышленности, а именно к способам получения полисахаридов из углеводсодержащих отходов переработки морских водорослей. Раскрывается способ получения полисахаридов из шрота (отходов переработки) бурых водорослей заключается в том, что слоевища водорослей экстрагируют, реакционную смесь разделяют на фракции, концентрируют, жидкий экстракт сушат, отличающийся тем, что в качестве сырья используют шрот (отходы переработки) водорослей, образующийся в процессе получения полифенольных экстрактов с помощью природных глубоких эвтектических растворителей (ПГЭР) на основе молочной кислоты, после отделения жидкого ПГЭР-экстракта фильтрацией или центрифугированием шрот водорослей загружают в экстрактор и экстрагируют при рН=2,0-5,0 при температуре 20-60°С в течение 1-24 ч. рН регулируют добавлением 10-80% раствора молочной кислоты, для интенсификации процесса экстракции и перемешивания среды применяют УЗ-аппарат типа "горн", затем реакционную ...

СОСТАВ ДЛЯ ЛЕЧЕНИЯ ОЖИРЕНИЯ

Использование: в области медицины. Предложен гомеопатический состав, применяемый при лечении ожирения: аспарагус, ацидум муратикум, фукус, миллефолиум, цистус и силицея. В состав для мужчин дополнительно введен иохимби, для женщин - аристолохия. Компоненты входят в состав в равных количествах.

СРЕДСТВО "ФИТОЛОН" И "ФИТОЛОН-М" ДЛЯ ПРОФИЛАКТИКИ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ

Использование: в фармакологии, а именно при создании профилактических средств при онкологических заболеваниях, вызванных различными факторами. Сущность: "Фитолон" содержит, мас.%: этиловый спирт 90 - 99,9; медные производные хлорофилла (МПХ) 0,02 - 0,05; воду остальное. "Фитолон - М" содержит, мас. %: этиловый спирт 90 - 99,9; МПХ 0,02 - 0,05; пищевой ароматизатор 0,1 - 0,5; воду остальное. МПХ эффективны в качестве средства для профилактики онкологических заболеваний. Повседневное применение МПХ необходимо для профилактики патологических процессов в организме людей, занятых в производствах, связанных с ионизирующим излучением и вредными химическими веществами, а также живущих в неблагоприятных экологических условиях. 1 з.п. ф-лы, 2 табл.

СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ С ХРОНИЧЕСКОЙ ЛИМФОВЕНОЗНОЙ НЕДОСТАТОЧНОСТЬЮ НИЖНИХ КОНЕЧНОСТЕЙ

Изобретение относится к медицине, а именно к восстановительной медицине и ангиологии, и может быть использовано для лечения больных с хронической лимфовенозной недостаточностью нижних конечностей. Для этого больному наносят гомогенезированный гель из бурых морских водорослей температурой 28-30°С с обертыванием конечностей неткаными салфетками (простынями). После этого без временного интервала осуществляют переменную пневматическую компрессию от аппарата «Лимфа-Э» на область нижних конечностей. При этом используют режим «восходящей волны с запоминанием давления», II режим работы, при давлении 60-90 мм рт.ст., экспозиции 40-60 минут. Процедуры проводят ежедневно, 5 раз в неделю с 2 днями перерыва. Курс лечения составляет 10-12 процедур. Способ обеспечивает повышение эффективности лечения при всех стадиях и при любой длительности заболевания в том числе за счет дополнительной стимуляции лимфодренажной функции, улучшения процессов микроциркуляции, периферической гемодинамики, показателей плазменно-коагуляционной ...

СПОСОБ ЛЕЧЕНИЯ СИНДРОМА ЗАДЕРЖКИ ВНУТРИУТРОБНОГО РАЗВИТИЯ ПЛОДА

Способ относится к медицине, в частности к акушерству, и может быть использован для уменьшения числа плодов с задержкой развития и улучшения перинатальных исходов. Предлагаемый способ осуществляется путем дополнительного включения в схему лекарственной терапии лечебных доз (3 - 4 г в день) кислородолипидобелково-углеводного комплекса Spirulina Platensis, до получения адекватной динамики роста плода при ультразвуковом сканировании (но не менее 2 недель) и последующем приеме поддерживающих доз (1,5 - 2 г в день) до срока родов. Способ позволяет снизить перинатальные потери путем пренатальной стимуляции метаболизма фетоплацентарной системы в комплексной терапии с ЗРП.

СПОСОБ ПРОБИОТИЧЕСКОЙ КОРРЕКЦИИ ПОСТИНТОКСИКАЦИОННОГО ПСИХОЗА У БОЛЬНЫХ СИНДРОМОМ ЗАВИСИМОСТИ ОТ АЛКОГОЛЯ

Изобретение относится к области медицины и фармакологии и представляет собой способ пробиотической коррекции постинтоксикационного психоза у больных синдромом зависимости от алкоголя, заключающийся в восстановлении функционирования печени за счет повышения детоксикационной и метаболической функций с применением БАД, содержащих пробиотические культуры бифидобактерии в дозе 10КОЕ/г 3 раза в сутки и лактобактерии в дозе 10КОЕ/г 3 раза в сутки в течение 5 дней. Изобретение обеспечивает снижение активности ферментов ACT, активацию пигментной и белково-синтетической функций печени, восстановление нормальной флоры толстой кишки. 2 пр.

СПОСОБ ПОЛУЧЕНИЯ ПРЕПАРАТА ДЛЯ СТИМУЛЯЦИИ НЕСПЕЦИФИЧЕСКОЙ РЕЗИСТЕНТНОСТИ ОРГАНИЗМА, ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ И РЕАЛИЗАЦИИ ВОСПРОИЗВОДИТЕЛЬНЫХ КАЧЕСТВ КРУПНОГО РОГАТОГО СКОТА

Изобретение относится к области биотехнологии и ветеринарной медицины, а именно к способу получения препарата для стимуляции неспецифической резистентности организма, профилактики заболеваний и реализации воспроизводительных качеств крупного рогатого скота, который включает смешивание 90 мас. ч. 0,2-0,3%-ной суспензии агара, 2,5 мас. ч. концентрата очищенного полисахаридного комплекса дрожжей, 3,5 мас. ч. (-)2,3,5,6-тетрагидро-6-фенилимидазо-[2,1-b]-тиазола гидрохлорида и 0,2 мас. ч. формалина, отличающемуся тем, что при смешивании дополнительно вводят 5000000 ME антибиотика бензилпенициллин натрия и 5000 мг антибиотика энрофлоксацин, объем препарата доводят дистиллированной водой до 100 мас. ч. Изобретение обеспечивает усиление действия на факторы неспецифической резистентности организма, активацию фагоцитоза и значительное расширение спектра бактерицидной активности против возбудителей заболеваний крупного рогатого скота. 4 табл., 4 пр.

Биологически активный препарат на основе водорослей

... 1. Биологически активный препарат на основе водорослей, содержащий лекарственные растения, водоросли, глицерин, отличающийся тем, что он дополнительно содержит ланолин, масло растительное, экстракт растительный, водоросли Spirulina Platensis, водоросли Laminaria japonica в виде гидролизата, ксантан при следующем соотношении компонентов, мас.%:2. Биологически активный препарат по п. 1, отличающийся тем, что в качестве экстракта растительного содержит 0,01-10 экстрактов, взятых из группы: экстракт водорослей Fucus vesiculosus, экстракт конского каштана, экстракт плюща, экстракт имбиря, экстракт виноградной косточки, экстракт гуараны, экстракт зеленого чая.3. Биологически активный препарат по п. 1, отличающийся тем, что в качестве смеси масел растительных содержит 0,005-0,5 эфирного масла и 0,005-9,5 масла косточковых.

БИОЛОГИЧЕСКИ АКТИВНАЯ ДОБАВКА К ПИЩЕ "МИГИКАЛЬГИН"

... 1. Биологически активная добавка к пище, содержащая альгинат кальция, отличающаяся тем, что дополнительно содержит белковый гидролизат из мяса моллюсков в количестве мас.ч.: альгинат кальция 210,5-280,0 белковый гидролизат из мяса моллюсков 190-240,0 2. Биологически активная добавка к пище по п.1, отличающаяся тем, что дополнительно содержит аскорбиновую кислоту и глюкозу.

СПОСОБ ПОЛУЧЕНИЯ КОМПЛЕКСНОЙ БИОЛОГИЧЕСКИ АКТИВНОЙ ДОБАВКИ К ПИЩЕ НА ОСНОВЕ МОРСКИХ ГИДРОБИОНТОВ (ВАРИАНТЫ)

Изобретение относится к рыбной промышленности, а именно к производству биологически активных добавок (БАД) к пище из морских гидробионтов, и может быть использовано в медицине, ветеринарии и косметике. Способ предусматривает иммобилизацию биологически активного вещества на полисахариде. При этом в качестве биологически активного вещества используют или раствор ферментативного гидролизата белково-пептидного комплекса животного происхождения, или раствор ферментативного гидролизата нуклеопротеидного комплекса животного происхождения, или раствор ферментативного гидролизата белково-олигосахаридного комплекса животного происхождения. В качестве полисахарида используют или деминерализованную суспензию хитана, или гелеобразный раствор соли альгиновой кислоты. При этом соблюдают соотношения ингредиентов в конечном продукте 1:3 по сухой массе соответственно. Дополнительно к ингредиентам добавляют 2,5-3,0% аскорбиновой кислоты. Полученную смесь выдерживают при постоянном помешивании в течение 1- ...

СПОСОБ ИЗВЛЕЧЕНИЯ ВОДОРАСТВОРИМЫХ КОМПОНЕНТОВ РАСТЕНИЙ

... 1. Способ извлечения водорастворимых компонентов растений, включающий промывку измельченного сырья дистиллированной водой, насыщенной озоном, порционную загрузку смеси сырья и воды в гомогенизатор роторного-пульсационного типа, извлечение биологически активных компонентов из растительного сырья и фасовку отличающийся тем, что в смесь сырья и воды добавляют чешуйчатый лед с температурой от -8 до -12°C, который приготавливают на дистиллированной воде или дистиллированной воде,. насыщенной углекислым газом, последующие порционные загрузки смеси сырья воды и чешуйчатого льда проводят при достижении температуры смеси в пределах от 20 до 30°С, при этом предварительное извлечение водорастворимых компонентов растительного сырья проводят при оборотах роторного-пульсационного гомогенизатора, составляющих от 10 до 50% от максимальных оборотов, окончательное извлечение водорастворимых компонентов из сырья проводят при максимальных оборотах роторного-пульсационного гомогенизатора и температуре смеси ...

СПОСОБ СНИЖЕНИЯ ВЕСА

CПOCOБ ПOЛУЧEHИЯ CPEДCTBA, OБЛAДAЮЩEГO ИMMУHOMOДУЛИPУЮЩEЙ AKTИBHOCTЬЮ

AGENT FOR CARE OF HAIRS

Способ получения средства, обладающего иммуномодулирующей активностью

Использование: изобретение относится к медицине и касается способа получения средства, обладающего иммуномодулирующей активностью. Целью является повышение специфической активности. Сущность изобретения заключается в экстракции растительного сбора, состоящего, мае. %: свежие листья алоэ древовидного 29-31; трава горца птичьего 9-11; трава клевера пашенного 9-11: листья вахты трехлистной 9-11; листья морской капусты 9-11; кода дуба 35- 25,40%-ным этиловым спиртом в течение 3-4 ч при температуре б5-75°С при соотно-. шении сырье: экстрагент 1:7-15 с последующим сгущением экстракта под вакуумом, сепарирования и сушки. Положительный эффект заключается в проявлении высокой иммуномодулирующей активности, а также в 2 раза повышает фагоцитирующую способность лейкоцитов. 1 табл.

"Сбор лекарственных трав для лечения сахарного диабета "Лидия 1,2,3""

Изобретение относится к химико-фармацевтической промышпенности Три варианта сбора используются поочередно или самостоятельно Сбор Лидия 1 содержит, г подорожник 35,0, корень лопуха 500 ламинария 600 кукурузные рыльца 400, зверобой 100 боярышник 1500. пустырник 1000 сушеница 2000 шиповник 1000 цикорий 500 душица 100 Сбор Лидия 2 содержит, г подорожник 350 кукурузные рыльца 40,0. зверобой 50,0, пустырник 500, сушеница 100.0, шиповник 50.0. цикорий 300 мята перечная 500, цветы бузины черной 500 семя льна 100.0. крапива 50.0 Сбор Лидия 3 содержит, г подорожник 35,0. корень лопуха 500 ламинария 100.0. зверобой 30.0, боярышник 50.0, пустырник 100.0, цикорий 50.0. душица 200. мята перечная 100,0, семя льна 100,0. крапива 150.0 лист черники 50.0, лавровый лист 50.0. почечный чай 500 Сборы оказывают общеукрепляющее, сахаропонижающее, противовоспалительное действие и нормализует микрососудистый кровоток.

Способ получения полифруктозана

HAUTREGENERIERENDE KOSMETISCHE MITTEL

The composition contains 0.5 to 40% of selenium-containing alga and 99.5 to 60% of unsaturated fatty acids or their derivatives in admixture with carriers and additives.

Use of purified siliceous earth containing silicic acid

Use of Terra Silicea purificata EB 6 (purified siliceous earth containing 87% silicic acid and obtained from sea bed algae), at e.g. 3 teaspoons daily, to strengthen bones and connective tissue and to promote healthy nails and hair. It combats greying of hair and promotes the recolouring of grey hair.

Entzündungshemmende Zusammensetzung

Mittel, insbesondere für Kosmetika, enthaltend DHEA und/oder Vorstufe oder Derivate davon, und mindestens eine Verbindung, die die Glykosaminoglykane-Synthese erhöht

Zusammensetzung zur Linderung von Gelenkschmerzen

Nahrungsergänzungsmittel in Form eines Nahrungsmittels oder eines Getränks umfassend ein Krillöl in Kombination mit Astaxanthin und Polymeren von Hyaluronsäure oder Natriumhyaluronat (Hyaluronan) mit geringem Molekulargewicht.

PHARMACEUTICAL COMPOSITIONS ACTING ON THE HEART AND CARDIOVASCULAR SYSTEM AND PROCESS FOR PREPARING SAME

Substances extracted from dictyotales, preparation method therefor, and compositions containing same.

Biological substances and particularly biologically active substances of marine origin are disclosed. The novel biologically active substances are extracts of plants of the dictyotales family and have characteristic analytical properties. A method for preparing said novel substances and pharmaceutical, cosmetic and/or food compositions containing such substances are also disclosed. Said biologically active substances are useful for preparing pharmaceutical, cosmetic and/or food compositions for altering the synthesis of glycosylated elements in the extracellular matrix of human and animal tissues.

Substances extracted from dictyotales preparation method therefor and compositions containing same

Substances extracted from dictyotales their process of obtaining and compositions while containing

Substances extracted from dictyotales preparation method therefor and compositions containing same

MEDICINE OUT LAMINARIN OR OLIGOLAMINARINEN FOR THE TREATMENT OF SEPTIKÄMIE AND SHOCK

AUF DAS HERZ-KREISLAUF-SYSTEM WIRKENDE ARZNEIMITTELPRAEPARATE UND VERFAHREN ZUR HERSTELLUNG DERSELBEN

USE SULFATED POLYSACCHARIDEN FOR THE TREATMENT OF THROMBOSEN

COMPOSITIONS FOR THE IMPROVEMENT OF THE INTESTINE HEALTH AND THE ANIMAL ACHIEVEMENT CONTAINING BETA GLUCANS AND ALFA FUCANS

COSMETIC AND DERMATOLOGI COMPOSITIONS ON BASIS OF ALGA EXCERPTS

CO-PERLCHEN OF DHA AND ROSMARIN AND USE PROCEDURES

USE OF LAMINARIN IN THE TREATMENT OF CANCER

SPOROPOLLENIN CONTAINING SOLUBLE COMPOSITION AND USE

ALGAE AS FOOD ADDITION OF THE INCREASE OF THE IMMUNE ANSWER IN MAMMALS

PERIDININ CHLOROPHYLL COMPLEX AS FLUORESCENT REGISTRATION NUMBERS.

LIMULUSTEST POSITIVE PFLANZENGLYKOLIPID AND PROCEDURES FOR THE STIMULATION OF THE IMMUNE SYSTEM OF AN ANIMAL.

FIBROUS CYANOBAKTERIEN EXCERPTS, THEIR MANUFACTURING PROCESSES AND THEIR ACTIVITY AS GROWTH FACTOR.

RAW EXCERPTS OF THE BLUE ALGA, MANUFACTURING METHOD AND USE IN THE KOSMETOLOGIE AND DERMATOLOGIE

Nierenfunktionsdiagnosticum and procedure for its production

ENTZÜNDUNGSHEMMENDE COMPOSITION

PROCEDURE FOR THE PREVENTIVE TREATMENT OF MASTITIS

LIME MATERIAL

ANTIULCEROGENES MEANS AND ADHESION INHIBITOR FOR HELICOBACTER PYLORI

PROCEDURE FOR THE CLEANING OF BETA CAROTIN

REMOVAL OF SLAG AND/OR REGENERATION MEANS

A ANTIOXYRIERUNGSMITTEL ON BASIS FROM PLANT EXTRACTS TO THE TREATMENT OF CYCLE AND FAT CRAZE PROBLEMS

CALCIUM CHANNEL ANTAGONIST WITH RESTRAINING EFFECT ON THE RELEASE OF PARATHYROIDHORMONEN AND ITS USE

Nutritional product for persons having a neurological injury

Cosmetic and dermatological formulations with natural pigments and methods of use

Furanone-initiated polymers

Polymers initiated with furanones and compositions containing such polymers are suitable for use in making textiles, medical devices, delivery agents, packaging materials, coatings for such items, and the like.

Oral preparation containing seaweed for reduction of plaque and calculus

Foodstuff compositions

Supplements containing annatto extracts and carotenoids and methods for using the same

SUPPLEMENTS CONTAINING ANNATTO EXTRACTS AND CAROTENOIDS AND METHODS FOR USING THE SAME

An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems

Halobacteria extracts composition for tumor reduction

The present invention provides a composition and method for treating solid tumors in a mammalian subject. The composition comprising halobacterial extracts containing antioxidants, comprising: (a) at least one water soluble fraction and, (b) at least one oil soluble fraction,wherein the halobacterial extract is adapted for therapeutic treatment of solid tumor reduction. Furthermore, the composition comprising halobacterial extract adapted to promote solid tumor reduction in radiation treatment in vitro and in vivo.

Microalgae extract containing omega3 -polyunsaturated fatty acids and method for extracting oil from micro-organisms

The present invention relates to a biphasic microalgae extract comprising 15-95 wt.% of an aqueous phase and 5-85 wt.% of an oil phase, said extract containing at least 1% by weight of total fatty acids of 3-fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and combinations thereof, said extract further being characterized in that it contains: 40-100% by weight of the oil phase of lipids selected from triglycerides, diglycerides, monoglycerides, phosphatides, free fatty acids and combinations thereof; 0.01-10% of carotenoids by weight of the oil phase; 0.5-10% of sodium chloride by weight of the aqueous phase; 0-3 wt.% of non-dissolved material other than dispersed droplets of aqueous phase or oil phase; and 0-10% of C ...

Docosahexaenoic acid, methods for its production and compounds containing the same

POTENTIATOR CONFERRING RESISTANCE TO INFECTION

Capsules with porous mineral cortex

Method for curing child's and adolescent myopia using a spiruline preparation

Use of dictyotal extracts in the production of a topical composition

PURIFIED COMPONENT OF BLUE-GREEN ALGAE AND METHOD OF USE

Disclosed herein are extracts of blue green algae, such as Aphanizomenonflos aquae, that are enriched for a selectin ligand, such as an L-selectin ligand. Selectin ligands isolated from blue-green algae cells are disclosed herein. Methods are described for isolating these selectin ligands. The purified selectin ligands are of use in inducing stem cell mobilization in a subject. Thus, methods for inducing stem cell isolation that include administering a therapeutically effective amount of the extract enriched form the selectin ligand, or an isolated selectin ligand, are disclosed herein.

AGENT FOR DIAGNOSING KIDNEY MALFUNCTION AND A METHOD FOR PRODUCING THE SAID AGENT

SKIN CREAM CONTAINING MARINE PLANKTON PRODUCTS

ANTICANCER AGENT

METHOD FOR THE EFFICIENT AND CONTINUOUS GROWTH AND HARVESTING OF MULTIPLE SPECIES OF PHYTOPLANKTON

Methods of growing and harvesting multiple phytoplankton species are disclosed. The method comprises: (1) transporting a first volume of phytoplankton seawater (FVPS) containing multiple species of naturally-occurring phytoplankton (MSNOP) directly from a source of seawater into at least one tank; (2) depriving the FVPS of light to form a first volume of light-deprived phytoplankton seawater (FVLDPS); (3) adding nutrients to the FVLDPS to proliferate the MSNOP to a predetermined density faster than the growth cycle of non-light deprived phytoplankton; (4) withdrawing a volume of the light-deprived phytoplankton seawater from the tank and adding a second volume of seawater containing MSNOP directly from the source of seawater to the tank to initiate the growth of phytoplankton, the second volume of seawater substantially equivalent to the volume of light-deprived phytoplankton seawater withdrawn from the tank; (5) separating the MSNOP from the withdrawn light-deprived phytoplankton seawater ...

ALGAL BASED EDIBLE VACCINES

The present invention provides edible vaccines comprising transgenic microalgae expressing at least one exogenous antigen or an intervening organism comprising the transgenic microalgae. The antigen expressing microalgae are used for oral delivery of the antigen to a target organism in its intact and functional form. The exogenous antigen, expressed in the microalgae, is characterized by exerting at least one immunogenic response in the subject consuming the vaccine.

TRANSGENIC MICROALGAE AND USE THEREOF AS A FEED FOR DELIVERY OF INTERFERING RNA MOLECULES

The present invention provides non-propagating transgenic microalgae expressing at least one heterologous RNAi molecule. The RNAi-expressing non-propagating transgenic microalgae are used for oral delivery of the RNAi molecule to a target organism in its intact and functional form. The heterologous RNAi molecule, present within the microalgae, is characterized by being biologically active, exerting at least one specific effect on the organism consuming the microalgae or on a pathogen of said organism. In particular, the non-propagating transgenic microalgae are used as agents for biological control of animal and plant pests.

TREATMENT METHODS

The present invention provides a method of treating a seaweed extract comprising a target molecule and a pyrogenic agent, the method comprising the step(s) of: inactivating the pyrogenic agent and/or removing the pyrogenic agent, wherein the method results in a reduction in pyrogenicity of the extract. The present methods are useful in the preparation of pharmaceutical compositions and biomaterials for which pyrogen removal is critical.

Verfahren zur Herstellung von Schleimsalben

Procédé de production de substances mitotiques

Conjugates of biologicals with acidic polysaccharides

A conjugate, forming sol. Na & insol. Ca salts, formed by covalent amide &/or ester linkage between: (1) an acidic polysaccharide, such as pectin, pectic acid, alginic acid, celluronic acid or carragheenin (2) a biochemically active substance of protein nature or contg. phenolic OH gps, such as an antigen or allergen, a micro-organism, toxin, toxoid, hormone, enzyme or hapten. For solubilising insol. biologicals with preservation of their activity; or for insolubilising a sol. enzyme, albumin or antigen. They are stable on storage in the dry state.

Verfahren zur Herstellung eines zur Anregung der Funktion des reticulo-endothelialen Systems geeigneten Stoffes aus einzelligen Grünalgen

Process for the preparation of germanium-containing algae

SKIN-REGENERATING COSMETIC COMPOSITION AND PROCEDURE FOR YOUR PRODUCTION.

A Biostimulant.

COMPOSITIONS OF MARINE BOTANICALS TO PROVIDE NUTRITION TO AGING AND ENVIRONMENTALLY DAMAGED SKIN

Disclosed is a topical skin composition comprising water, a first algae extract comprising , a second algae extract comprising , and a third algae extract. 1. A topical skin composition comprising:(a) water;{'i': 'Crithmum maritimum;', '(b) a first algae extract comprising'}{'i': 'Ulva lactuca', '(c) a second algae extract comprising ; and'}(d) a third algae extract.2. The topical skin composition of claim 1 , wherein the composition is formulated as a cream or lotion.3. The topical skin composition of claim 1 , wherein the composition is formulated as a gel or solution.4. The topical skin composition of claim 1 , wherein the composition further comprises a paraben.5. The topical skin composition of claim 4 , wherein the paraben is methylparaben or propylparaben or both.6. The topical skin composition of claim 4 , wherein the composition further includes a moisturizer and a vitamin.7. The topical skin composition of claim 6 , wherein the moisturizer is propylene glycol claim 6 , glycerin claim 6 , or a phospholipid.8. The topical skin composition of claim 7 , wherein the composition includes propylene glycol claim 7 , glycerin and a phospholipid.9. The topical skin composition of claim 8 , wherein the composition further includes potassium sorbate.10. The topical skin composition of claim 6 , wherein the vitamin is retinol claim 6 , retinyl palmitate claim 6 , tocopherol claim 6 , or tocopheryl acetate.11. The topical skin composition of claim 10 , wherein the composition includes a combination of retinol or retinyl palmitate and tocopherol or tocopheryl acetate.12. The topical skin composition of claim 1 , wherein the composition includes from about 0.001% to about 5% by weight of the first algae extract claim 1 , from about 0.001% to about 5% by weight of the second algae extract claim 1 , and from about 0.001% to about 5% by weight of the third algae extract.13Monostroma.. The topical skin composition of claim 1 , wherein the composition does not include an algae ...

ANTALGIC MAT FOR MULTIPLE AND MAGNETIC THERAPY

A pain-relieving mat for multiple and magnetic therapy is composed of a tissue of bioceramic fibre, magnetic bands of north-south magnetization, central magnetic bands, a lower tissue, configured to allow connecting the mat to any generator device for magnetotherapy, and engineered yarns, such as copper fibre, carbon fibre, silver fibre. 1. A pain-relieving mat for multiple and magnetic therapy , comprising at least:a. a first tissue composed of at least one bioceramic fibre,b. two pairs of magnetic bands for a north-south magnetization located at the ends of said mat, so as to be arranged, during use, two at the feet side and two at the head side,c. central magnetic bands, with respect to the length of the mat, i. allow connecting the mat to a generator device for magnetotherapy, configured to generate high and/or low frequency electromagnetic waves in,', 'ii. generate a monopolar radio magnetic field on the tissue and which, in an operative configuration, is regularly emitted in a homogeneous manner on the entire area of interest, or singularly or simultaneously with nuclei to generate a low frequency., 'd. a lower tissue, configured toe. one or more engineered yarns, such as copper fibre, carbon fibre, silver fibre.2. The mat according to claim 1 , wherein a wire exits claim 1 , which ends in a small metal ball that is configured to contact the floor claim 1 , in an operative configuration claim 1 , discharging the energy built up during the day.3. The mat according to claim 1 , wherein along at least one edge it comprises a carbon double wire.4. The mat according to claim 1 , wherein the upper side of the mat is made of silver fibre.5. The mat according to claim 1 , wherein copper filaments for the complete discharge of the electrostatic energy are present within the first tissue.6. The mat according to claim 1 , which further comprises a suitable jack connectable claim 1 , in an operative configuration claim 1 , to a magnetotherapy apparatus and/or a low-high ...

IMMUNE BALANCE REGULATOR

The present invention provides a novel immune balance regulator that regulates an immune balance in a living body. The immune balance regulator contains a -derived material and regulates an immune balance between Th1, Th2, and Th17, which is a balance between immune responses individually induced by Th1, Th2, and Th17 in a living body. The immune balance regulator regulates the immune balance between Th1, Th2, and Th17 so that immune responses induced by Th1 become relatively dominant over immune responses induced by Th2 or Th17 to improve a physical constitution that has an immune imbalance of Th1, Th2, and Th17 shifted towards Th2 and to prevent or treat a disease associated with the immune imbalance of Th1, Th2, and Th17 shifted towards a Th2 dominance. The immune balance regulator is administered prior to expected onset of a disease associated with the immune imbalance of Th1, Th2, and Th17 shifted towards the Th2 dominance. 1. A method for improving a physical constitution that has an immune imbalance of Th1 , Th2 , and Th17 shifted towards a Th1 , a Th2 and/or a Th17 dominance , the method comprising administering to a subject in need of immune balance an effective amount an immune balance regulator comprising:{'i': 'Euglena', 'a -derived material,'}wherein the immune balance regulator regulates an immune balance between Th1, Th2, and Th17, the immune balance being a balance between immune responses individually induced by Th1, Th2, and Th17 in a living body, andwherein the improving a physical constitution is preventing or treating influenza, peptic ulcer, or articular rheumatism.2. The method according to claim 1 , wherein the regulator regulates the immune balance between Th1 claim 1 , Th2 claim 1 , and Th17 so that immune responses induced by Th1 become relatively dominant over immune responses induced by Th2 or Th17.3. The method according to claim 1 , wherein the immune imbalance of Th1 claim 1 , Th2 claim 1 , and Th17 is shifted towards a Th2 dominance. ...

CONTROLLED GROWTH OF MICROORGANISMS

It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types. 1. A first microbial cell comprising a nucleic acid encoding a secreted bacteriocin which controls the growth of a second microbial cell and a nucleic acid which confers resistance to said secreted bacteriocin , wherein said first microbial cell has been genetically engineered to allow the expression or activity of said nucleic acid which confers resistance to said bacteriocin to be regulated.2. The first microbial cell of claim 1 , wherein the expression or activity of said nucleic acid which confers resistance to said bacteriocin is reduced to a level which causes said first microbial cell to be neutralized by said bacteriocin if said first microbial cell is released from a desired growth environment.3. The first microbial cell of claim 1 , wherein said first microbial cell has been genetically engineered to make a desired product.4. The first microbial cell of claim 3 , wherein said secreted bacteriocin further has been selected to maintain at least one condition within a culture in which said first microbial cell is producing said desired product.5. The first microbial cell of claim 4 , wherein the culture comprises at least one invading microbial organism.6. The first microbial cell of claim 4 , wherein the at least one condition within a culture comprises controlling the growth of the second microbial cell claim 4 , wherein the second microbial cell is a common contaminate of the culture.7. The first microbial cell of claim 1 , wherein said second microbial ...

Method for the Stimulation of Human Immune Cells

Provided herein is a substance for use in a therapeutic method for stimulating cells in the human immune system, a method for producing this substance, and a method of use of the substance for stimulating cells of the human immune system in treating various diseases involving immune system disorders.

Reducing the Risk of Pathological Effects of Traumatic Brain Injury

The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury. 1. A method for reducing the risk of pathological effects of traumatic brain injury , comprising:(a) administering to a subject who is at risk of traumatic brain injury a composition comprising docosahexaenoate (DHA), wherein the composition is administered in a prophylactically effective amount for a sufficient time period prior to engagement in an activity associated with a risk of traumatic brain injury to reduce the risk of pathological effects of traumatic brain injury, and wherein the composition has an eicosapentaenoate (EPA) content of about 3 wt % of the total fatty acid content.2. A method for reducing the risk of pathological effects of traumatic brain injury , comprising;(a) selecting a subject who is at risk of traumatic brain injury; and(b) administering to the subject a composition comprising docosahexaenoate (DHA), wherein the composition is administered in a prophylactically effective amount for a sufficient time period prior to engagement in an activity associated with a risk of traumatic brain injury to reduce the risk of pathological effects of traumatic brain injury.3. (canceled)4. The method of or in which the DHA is in the form of an alkylester.5. The method of in which the DHA alkylester is a methyl claim 4 , ethyl or propyl ester.6. The method of or in which the DHA alkylester is at least about 85 wt % of the total fatty acid content of the composition.7. The method of in which the DHA alkylester is about 85 to about 96 wt % of the total fatty acid content of the composition.8. The method of or in which the DHA is at least about 40 wt % of the total fatty acid content of the composition.9. The method of in which the DHA is about 40 to about 50 wt % of the total fatty acid content of the composition.10. The method of or in which the DHA is at least about 55 wt % of the total fatty acid content of the composition.11 ...

PRODUCTION PROMOTER OF TYPE I COLLAGEN OR ELASTIN

A type I collagen or elastin production promoter containing a mycosporine-like amino acid or a salt thereof as an active ingredient; and a method for promoting type I collagen or elastin production, the method including administering an effective amount of a mycosporine-like amino acid or a salt thereof. 112-. (canceled)13. A method for promoting type I collagen or elastin production , the method comprising administering an effective amount of a mycosporine-like amino acid or a salt thereof.14. The method according to claim 13 , wherein the mycosporine-like amino acid or the salt thereof is derived from algae.15. A method for promoting type I collagen gene or elastin gene expression claim 13 , the method comprising administering an effective amount of a mycosporine-like amino acid or a salt thereof.16. The method according to claim 15 , wherein the mycosporine-like amino acid or the salt thereof is derived from algae. Type I collagen, a fibrillar collagen, is abundant in bones and skins and responsible for bone and skin elasticity. Elastin is a fiber that has a role of supporting collagen fibers. The elastin content of the human skin dermis is said to be about 2% to 5%. The elastin content decreases with age to cause winkles. To prevent or reduce winkles or other signs, type I collagen or elastin is applied or orally administered.However, it is unclear whether type I collagen or elastin in foods or cosmetics is efficiently absorbed and reaches the site of action.Mycosporine-like amino acids, a family of amino acids found in algae, scallops, and other organisms, are known to have an effect of absorbing ultraviolet radiation (Non Patent Literature 1) and an effect of promoting fibroblast growth (Patent Literature 1). Mycosporine-like amino acids are also known to have an effect of promoting hyaluronic acid production (Patent Literature 2).Patent Literature 1: JP 2007-16004 APatent Literature 2: JP 6272814 B1Non Patent Literature 1: Phycol. 34, 418-430 (1998)Since it ...

Method for Drying-Conservation of Natural Substances

The invention comprises of an implementation of the lyophilization process in a method for a large-scale preservation of the entire biological material prior to the extraction and/or the utilization/manipulation of any substances of the biological content. The drying-conservation of all the natural substances is achieved via deep-freezing evaporation followed by complete drying of the biological material by the means of sublimation, and other additional manipulations and procedures suitable for the preparation of various commercially viable products further on. 1. A method for obtaining biological material and substances followed by commercially viable preparation and preservation of plants , funguses , lichens and algae , entire plant- , fungus- , lichen- or algae material , parts of entire plant- , fungus- , lichen- or algae species and/or any desired combinations of these species or parts of them , or mixes of them including but not limited to those serving herbal , medicinal and supplemental properties and purposes , with sad method comprising of the following steps , manipulations and conditions listed below in a non-successive order:rapid instantaneous deep freezing of the entire plant-, fungus-, lichen- and/or algae material used for commercial purposes shortly after the material collection, within minutes (less than two hours, but preferably within 20 minutes or less), before the vitality of the cells is destroyed,—by the means of using (preferably but not limited to) liquefied and/or solidified deep-freezing liquids or gases to momentarily submerse the biological material with their deep-cold solid-, liquid- or gaseous state (molecules) in certain enclosed volumes resulting in instant rapid deep freezing of the biological material to temperatures below minus−30 degree Celsius (° C.), and by the means of using preferably but not limited to liquid nitrogen (at minus−180° C. to minus−170° C.), dry ice (carbon dioxide) (at minus−80° C. to minus−30° C.) or else ...

Indian wax water/ zea mays

Indian Wax Water/Indian Algae is a distinct new water technology using different kinds of waxes and plant extracts to create, promote health—healing, medicine, medicinal mixtures, beauty, purification methods, cell regeneration, organic matter, gardening, hydroponics, new plant forms, Indian Algae, futuristic products based on wax water technology. New molecule structures and polymerization promotes healing for HIV, AIDS and other numerous diseases, E.coli , parasitic disorders internal or external. In combination with natural water types—spring, rain, sulfate, ocean and catalyst, mineral enhanced, purified, distilled, carbonated, and botanical.

Agents and Mechanisms for Treating Hypercholesterolemia

A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual. 1. A method of treating hypercholesterolemia in a patient , including the steps of:administrating an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism.2. A method of regulating cholesterol levels in a patient , including the steps of:administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, and/or chemically synthesized analogues of the components of PAZ, andregulating the expression of genes involved in lipoprotein metabolism.3. The method of claim 2 , wherein the composition is a liquid oral supplement.4. The method of claim 2 , wherein the composition is a nutraceutical.5. The method of claim 4 , wherein the composition is a food additive.6. The method of claim 2 , wherein said administration step is further defined as administering the composition daily.7. The method of claim 2 , wherein said regulating step is further defined as lowering total plasma cholesterol (TC) levels claim 2 , lowering low-density lipoprotein (LDL) levels claim 2 , and raising high- ...

SELECTING, PRODUCING, AND FEEDING WHOLE ALGAE AS A FEED SUPPLEMENT FOR CATTLE AND BISON TO PRODUCE MEAT HIGH IN OMEGA 3'S FOR HUMAN HEALTH

The present invention is a system and method for creating and using algae as a food supplement for cattle and buffalo thereby providing a desirable food supplement for cattle and buffalo wherein the meat and fat produced has increased specific Omega-3 polyunsaturated fatty acids for a product, which imparts a healthier cardiovascular or healthier central nervous system. 14-. (canceled)5. A method for increasing omega-3 highly unsaturated fatty acid content in beef for human consumption which comprises feeding to cattle , without suppressing the remainder of feed intake of said cattle and without reducing daily gain of said cattle measured by pounds of body weight per day , an effective amount for increasing the level of omega-3 highly unsaturated fatty acid content in the beef of an algae having a high level of Omega-3 fatty acids and a cell wall that is not digestible in the rumen of cattle.6Schizochytrium.. The method of wherein the algae is7Schizochytrium. The method of wherein the effective amount of the is between about 0.8 and about 1.0 pounds per day with corn.8chizochytrium. The method of wherein the effective amount of the is between about 2 to about 3 pounds per day with wheat or barley.9Schizochytrium;. A method for increasing omega-3 highly unsaturated fatty acid content in beef for human consumption claim 6 , consisting essentially of feeding to cattle claim 6 , without suppressing the remainder of feed intake of said cattle and without reducing daily gain of said cattle measured by pounds of body weight per day claim 6 , an effective amount for increasing omega-3 highly unsaturated fatty acid content in the beef of a corn; and at least one ingredient selected from the group consisting of soy claim 6 , alfalfa claim 6 , straw and wet grain distillers.10. The method of wherein the effective amount is between about 0.8 and about 1.0 pounds per day.11Schizochytrium. The method of for increasing omega-3 highly unsaturated fatty acid content in beef for ...

COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-KB

The present invention discloses a composition and method for effecting various cytokines and NF-κB by administering an effective amount of a phyto-percolate composition to an individual. In various exemplary embodiments, the composition is claimed to be useful for the effective treatment of inflammation, cancer, and/or various infections including HIV by regulation of various interleukins, such as IL-10 and IL-2, and of transcription factors including NF-κB. 1. A method of treating inflammation in a subject in need thereof; the method comprising administering an effective amount of phyto-percolate derived from culturing microorganisms of ATCC Deposit #PTA-5863 wherein the inflammation is treated by the phyto-percolate up regulating anti-inflammatory cytokines while down regulating pro-inflammatory cytokines.2. The method of claim 1 , wherein the anti-inflammatory cytokines comprise IL-10 and the inflammatory cytokines comprise IL-2.3. The method of claim 1 , wherein the inflammatory cytokines comprise TNF-α.4. The method of claim 1 , wherein the inflammatory cytokines comprise IFN-γ.5. The method of claim 1 , wherein the anti-inflammatory cytokines comprise IL-10 and the inflammatory cytokines comprise IL-2 claim 1 , TNF-α claim 1 , and IFN-γ.6. The method of claim 1 , wherein the phyto-percolate affects the expression of cytokines on a cellular level.7. The method of claim 1 , wherein the phyto-percolate further affects the activation of NF-κB.8. A method of affecting NF-κB in a subject in need thereof; said method comprising administering an effective amount of phyto-percolate derived from culturing microorganisms of ATCC Deposit #PTA-5863 to reduce the overall amount of NF-κB.9. The method of claim 8 , wherein the affecting of NF-κB occurs by decreasing expression claim 8 , activation or the DNA-binding activity of NF-κB.10. The method of claim 8 , wherein the affecting of NF-κB reduces inflammation.11. The method of claim 8 , wherein the affecting of NF-κB ...

Transgenic Microalgae And Use Thereof For Oral Delivery Of Proteins

Transgenic microalgae expressing at least one exogenous biologically active protein. The protein-expressing microalgae are used for the oral delivery of the biologically active protein to the target organism in its intact and functional form. The exogenous protein, expressed in algae, is characterized by being biologically active, exerting at least one specific activity having a beneficial effect on the subject consuming the algae. The transgenic microalgae are used as animal food for aquatic or land animals welfare or as food supplement for human healthcare. 1. A transgenic eukaryotic microalga comprising an expression cassette comprising at least one transcribable polynucleotide encoding a biologically active exogenous protein , the biologically active exogenous protein expressed within a subcellular compartment of the microalga cell.2. The transgenic microalga of claim 1 , wherein the subcellular compartment is selected from the group consisting of cell vacuole claim 1 , endoplasmic reticulum claim 1 , Golgi system claim 1 , lysosome claim 1 , and peroxisome.3. The transgenic microalga of claim 2 , wherein the subcellular compartment is the cell vacuole.4. The transgenic microalga of claim 3 , wherein the expression cassette further comprises a polynucleotide encoding a vacuole targeting peptide.5. The transgenic microalga of claim 4 , wherein the polynucleotide encoding a vacuole targeting peptide comprises the nucleic acid sequence set forth in SEQ ID NO:18 claim 4 , encoding the amino acid sequence set forth in SEQ ID NO:4.6. The transgenic microalga of claim 2 , wherein the subcellular compartment is the cell endoplasmic reticulum (ER).7. The transgenic microalga of claim 6 , wherein the expression cassette further comprises a polynucleotide encoding an ER targeting peptide.8. The transgenic microalga of claim 1 , wherein the expression cassette further comprises a polynucleotide encoding a protein domain that enhances the uptake of the expressed exogenous ...

SELECTING, PRODUCING, AND FEEDING WHOLE ALGAE AS A FEED SUPPLEMENT FOR CATTLE AND BISON TO PRODUCE MEAT HIGH IN OMEGA 3'S FOR HUMAN HEALTH

The present invention is a system and method for creating and using algae as a food supplement for cattle and buffalo thereby providing a desirable food supplement for cattle and buffalo wherein the meat and fat produced has increased specific Omega-3 polyunsaturated fatty acids for a product, which imparts a healthier cardiovascular or healthier central nervous system. 1. A method for increasing the omega-3 highly unsaturated fatty acid content of meat for human consumption comprising feeding algae to cattle without suppressing the remainder of the feed intake of said cattle and without reducing the daily gain as measured by pounds of body weight per day of said cattle wherein said algae comprises an omega-3 unsaturated fatty acid content of about 25 percent of total weight in an effective amount to increase the content of omega-3 highly unsaturated fatty acids in said beef.2. The method of wherein said effective amount is about 0.8 to 1.0 pounds of said algae per day with corn claim 1 , and is 2 to 3 pounds per day with wheat or barley.3. A method for increasing the omega-3 highly unsaturated fatty acid content of beef for human consumption comprising feeding algae to buffalo wherein said algae comprises an omega-3 unsaturated fatty acid content of about 25% percent of total weight in an effective amount to increase the content of omega-3 highly unsaturated fatty acids in said beef.45. The method of claim wherein said effective amount is about 0.8 to 1.0 ponds of said algae per day with corn and 2 to 3 pounds per day when wheat or barley. 1. Field of the Inventionin general, the present invention is a composition, system and method of creating and using whole algae as a food supplement for animals. The algae are high in omega 3s DHA and or EPA (and other constituents) in relation to total fats, and are suitable for cattle and bison's digestive system. The resulting meat with high DHA and EPA provides a superior beef with heart healthy properties and other healthy ...

Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same

The present invention relates to compositions comprising at least about 8% β-glucans and/or at least about 8% α-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising β-glucans and/or α-fucans. 1. A method of treating animals or humans comprising:feeding the animals or humans a composition comprising at least one of:at least 8% w/w partially hydrolysed β-glucans, and/or{'i': E. coli', 'Salmonella, 'at least 8% w/w partially hydrolysed α-fucans, in an effective amount to at least one of: promote the growth of beneficial microbes and reduce the levels of harmful microbes selected from or in animal or human intestines, improve gut structure, gut inflammation, nutrient digestibility, mineral absorption and growth performance in animals or humans, or act as a replacement for in-feed antibiotics and treatment for gut infection and inflammation, wherein the composition is formulated for oral delivery.'}2. The method of claim 1 , wherein the β-glucans comprise at least 8% w/w.3. The method of claim 1 , wherein the α-fucans comprise at least 8% w/w.4. The method of claim 1 , wherein the β-glucans comprise β-(1 claim 1 , 3)(1 claim 1 , 6)-glucans.5. The method of claim 1 , The composition according to claim 1 , wherein the β-glucans or the α-fucans are derived from a seaweed.6. The method of claim 1 , wherein the β-glucans comprise laminarin.7. The method of claim 1 , wherein the α-fucans comprise fucoidan.8Laminariaceae, FucaceaeGigartinaceae, Ascophyllum, Laminaria, Durvillea, Macrocystis, Chondrus, Ecklonia. The method of claim 8 , wherein the seaweed is selected from and or any combinations thereof.9. The method of claim 1 , further comprising mannitol claim 1 , lactose or combinations thereof.10. The method of claim 1 , wherein the β-glucans or α-fucans are derived from seaweed by acid-extraction.11. The method ...

COMPOUNDS AND METHODS FOR AFFECTING CYTOKINES

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-α, lactoferrin, IFN-γ, IL-1β, serum amyloid-A (SAA), IL-6 and/or β-defensin associated with infection or an immune response generally. 1. A method of treating mastitis in a cow , said method comprising administering to said cow a therapeutically effective amount of one or more isolates or fractions of phyto-percolate derived from culturing microorganisms of ATCC Deposit No. PTA-5863.2. The method of claim 1 , wherein said one or more isolates or fractions up-regulate at least one anti-inflammatory cytokine in bovine mammary epithelial cells claim 1 , and/or down-regulate at least one pro-inflammatory cytokine in bovine mammary epithelial cells.3. The method of claim 2 , wherein each of said cytokines is selected from the group consisting of TNF-α claim 2 , lactoferrin claim 2 , IFN-γ claim 2 , IL-1β claim 2 , serum amyloid-A (SAA) claim 2 , IL-6 and β-defensin.4. The method of claim 1 , wherein said one or more isolates or fractions each comprise at least one major bioactive species having a molecular weight of 452 Dalton or 678 Dalton.5. The method of claim 1 , wherein said one or more isolates or fractions include at least one component identified by having a liquid chromatogram (LC) retention time of about 0.58 minutes claim 1 , about 2.43 minutes claim 1 , about 2.93 minutes claim 1 , from about 3.14 to about 3.30 minutes claim 1 , from about 3.50 to about 3.70 minutes claim 1 , about 3.78 minutes claim 1 , about 4.07 minutes claim 1 , about 4.35 minutes claim 1 , about 4.92 minutes claim 1 , about 5.14 minutes claim 1 , about 5.57 minutes claim 1 , about 6.99 minutes ...

METHODS FOR PRODUCING BROWN ALGAE OF REDUCED IODINE CONTENT

The present invention aims to provide methods for producing brown algae or brown algal extracts of reduced iodine content while retaining the structures of pigment components in the brown algae. 1. A method for producing a brown alga of reduced iodine content while retaining a pigment component in the brown alga , which method comprises:shredding an untreated brown algal starting material and thereafter performing a heating treatment with hot water at 90-100° C. for 90-300 seconds; andsubjecting the resulting heat treated brown alga to extraction using hydrous ethanol at a concentration of 60-100%.2. (canceled)3. The method according to claim 1 , wherein the pigment component is chlorophyll c and/or fucoxanthin.4. The method according to claim 1 , wherein the chlorophyll c/iodine ratio is 0.32 or above claim 1 , and the fucoxanthin/iodine ratio is 0.23 or above.5hormeriAgardhkuromeLaminariaceae. The method according to claim 1 , wherein the brown alga is selected from the group consisting of (Turner) C. claim 1 , cava Kjellman claim 1 , Okamura claim 1 , and kelp (Bory).67.-. (canceled) The present invention relates to methods for producing brown algae or brown algal extracts that have the iodine content reduced while retaining pigment components such as chlorophyll c and fucoxanthin in the brown algae; the present invention also relates to brown algae or brown algal extracts obtained by said methods.Brown algae contain pigment components such as chlorophyll c and fucoxanthin that are beneficiary to health and, if ingested continuously, they are expected to bring about various efficacies favorable to health. To be more specific, the Applicant recently found that chlorophyll c has a degranulation suppressing action and are useful in suppressing allergic diseases and bone joint diseases (see Patent Document 1). Heretofore, experiments have been conducted to administer chlorophyll c2 to animal models with allergic rhinitis, demonstrating its ability to alleviate ...

GENETIC MODULATION OF PHOTOSYNTHETIC ORGANISMS FOR IMPROVED GROWTH

Mutant photosynthetic organisms having reduced chlorophyll and increased photosynthetic efficiency are provided. The mutant strains have mutated or attenuated: chloroplastic SRP54 gene and SGI1 gene; chloroplastic SRP54 gene and SGI2 gene; chloroplastic SRP54 gene, SGI1, and SGI2 genes are disclosed. The mutant photosynthetic organisms exhibit increased productivity with respect to wild-type strains. Also provided are mutant photosynthetic organisms having mutated or attenuated cytosolic SRP54 genes. Provided herein are methods of producing biomass and other products such as lipids using strains having mutations in an SRP54 gene, SGI1, SGI2 genes, a combination of SGI1/SRP54, and a combination of SGI2 and SRP54 genes. Also included are constructs and methods for attenuating or disrupting SRP54, SGI1, and SGI2 genes. 1. A mutant photosynthetic organism comprising a mutated or attenuated gene encoding a chloroplastic signal recognition protein 54 (cpSRP54) and a mutated or attenuated significant growth improvement gene 2 (SGI2).2. A mutant photosynthetic organism comprising a mutated or attenuated gene encoding a significant growth improvement gene 2 (SGI2).3. A mutant photosynthetic organism of claim 1 , further comprising a mutated or attenuated gene encoding a significant growth improvement gene 1 (SGI1) gene.4. A mutant photosynthetic organism according of claim 1 , wherein the mutant exhibits a reduction in chlorophyll under low light conditions and higher maximum quantum yield of photochemistry in photosystem II (F/F) at all physiologically relevant irradiances above 100 μE mswith respect to a control photosynthetic organism of the same species.5. A mutant photosynthetic organism according to claim 4 , wherein the mutant photosynthetic organism exhibits a reduction in chlorophyll of at least 20% reduction with respect to a control photosynthetic organism of the same species.6. A mutant photosynthetic organism of claim 1 , wherein the mutant exhibits lower ...

Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them

In alternative embodiments, provided herein are transcription/translation (TX-TL) systems and methods of using them for use as rapid prototyping platforms for the synthesis, modification and identification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites, from biosynthetic gene cluster pipelines. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the combinatorial biosynthesis of natural products (NPs), natural product analogs (NPAs) and secondary metabolites. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the rapid prototyping of complex biosynthetic pathways as a way to rapidly assess combinatorial and biosynthetic designs before moving to cellular hosts. In alternative embodiments, these exemplary TX-TL systems are multiplexed for high-throughput (HT) automation and for prototyping engineered platforms for the synthesis or modification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites analogs.

Cesium Eliminator

A dietary supplement comprising powdered ingredients: zeolite powder: 70%-5%, dehydrated seaweed: 5%-25%, seawater extract: 5%-10% 5%-10% and 5%-10%, methods of making and using the composition. 1. A dietary supplement composition , comprising:powdered ingredientsa) Zeolite powder: 70%-95 wt. %b) Dehydrated seaweed: 5%-25 wt. %c) Seawater extract: 5%-10 wt. %{'i': 'Chlorella:', 'd) 5%-10 wt. %'}{'i': 'Spirulina:', 'e) 5%-10 wt. %'}wherein particle sizes for all particles are from #40 mesh to #100 mesh.2. The composition of which is provided in a capsule.3. The composition of claim 1 , wherein a) is approximately #50 mesh claim 1 , b) is approximately #100 mesh claim 1 , c) is approximately #60 mesh claim 1 , d) is approximately #40 mesh claim 1 , and e) is approximately #40 mesh.4. The composition of claim 1 , wherein about 99% of particles in the composition are larger than 5 microns in diameter.5. The composition of claims 1 , wherein the final composition is encapsulated in water-soluble veggie capsules.6. A method of producing a dietary supplement composition claims 1 , comprising:combining powdered ingredients as follows,a) Zeolite powder: 70%-95 wt. %b) Dehydrated seaweed: 5%-25 wt. %c) Seawater extract: 5%-10 wt. %{'i': 'Chlorella:', 'd) 5%-10 wt. %'}{'i': 'Spirulina:', 'e) 5%-10 wt. %,'}wherein particle sizes for all particles are from #40 mesh to #100 mesh.7. The method of claim 6 , wherein a) is approximately #50 mesh claim 6 , b) is approximately #100 mesh claim 6 , c) is approximately #60 mesh claim 6 , d) is approximately #40 mesh claim 6 , and e) is approximately #40 mesh.8. The method of claim 6 , wherein about 99% of particles in the composition are larger than 5 microns in diameter.9. The method of claim 6 , wherein the composition is manufactured in an environment free of airborne heavy metals.10. The method of claim 6 , wherein the final composition is encapsulated in water-soluble veggie capsules.11. A method of causing cesium isotopes to be ...

FOOD SUPPLEMENT

A composition comprising at least 50 mg/g of one or several omega-3 type fatty acid(s), at least 10 mg/g of one or several xanthophyll(s), at least 1 mg/g of one or several sterol(s) and at least 2 μg/g of one or several phycoprostane(s), and its applications in particular as a food supplement in the prevention of the apparition of cognitive disorders. 1. A composition comprising at least 50 mg/g of one or several omega-3 type fatty acid(s) , at least 10 mg/g of one or several xanthophyll(s) , at least 1 mg/g of one or several sterol(s) and at least 2 μg/g of one or several phycoprostane(s).2. The composition according to claim 1 , wherein it comprises 50 to 250 mg/g of one or several omega-3 type fatty acid(s) claim 1 , 10 to 50 mg/g of one or several xanthophyll(s) claim 1 , 1 to 20 mg/g of one or several sterol(s) claim 1 , 2 to 100 μg/g of one or several phycoprostane(s).3. The composition according to claim 1 , wherein it comprises 50 to 200 mg/g of one or several omega-3 type fatty acid(s) claim 1 , 10 to 30 mg/g of one or several xanthophyll(s) claim 1 , 1 to 8 mg/g of one or several sterol(s) and 2 to 50 μg/g of one or several phycoprostane(s).4. The composition according to claim 1 , wherein it comprises 50 to 170 mg/g of one or several omega-3 type fatty acid(s) claim 1 , 10 to 25 mg/g of one or several xanthophyll(s) claim 1 , 1 to 6 mg/g of one or several sterol(s) and 2 to 40 μg/g of one or several phycoprostane(s).5. A food supplement comprising a composition according to claim 1 , and at least one oil selected from medium-chain triglycerides (MCT).6. The food supplement according to claim 5 , wherein the medium-chain triglycerides (MCT) are selected from coconut palm oil and palm oil.7. The composition according to claim 1 , wherein the or at least one of the omega-3 type fatty acids is selected from stearidonic acid (SDA) claim 1 , eicosapentaenoic acid (EPA) claim 1 , docosahexaenoic acid (DHA) and mixtures thereof.8. The composition according to ...

GEL CAPSULE COMPRISING A PLANT CELL

Disclosed is a capsule including: an internal phase including at least one plant cell; and an external gel phase, that totally encapsulates the internal phase at its periphery, the external phase including at least one surfactant and at least one polyelectrolyte in the gel state. 1. A capsule comprising :an internal phase comprising at least one plant cell; andan external gel phase, that totally encapsulates said internal phase at its periphery, said external phase comprising at least one surfactant and at least one polyelectrolyte in the gel state.2. A capsule according to claim 1 , in which the internal phase comprises a culture medium.3. A capsule according to claim 1 , in which the plant cell or cells are algae cells.4. A capsule according to claim 1 , in which the plant cell or cells are in suspension in the internal phase.5. A capsule according to claim 1 , in which the polyelectrolyte is a polyelectrolyte reactive to multivalent ions.6. A capsule according to claim 1 , wherein the capsule size is less than 5 mm.7. A method for culturing plant cells including a step of putting in culture at least one capsule according to .8. A method for producing a compound of interest claim 1 , that includes:a step of putting in culture at least one capsule according to claim, said capsule comprising at least one plant cell that is capable of producing said compound of interest.possibly, a step of elicitation of the plant cells included in said capsule; anda step of recovering the compound of interest.9. Plant cells produced using the capsule according to one .10. A composition comprising at least one capsule according to .11. A capsule according to claim 2 , in which the plant cell or cells are algae cells.12. The capsule of claim 3 , wherein the algae cells are micro algae cells.13. A capsule according to claim 2 , in which the plant cell or cells are in suspension in the internal phase.14. A capsule according to claim 3 , in which the plant cell or cells are in suspension ...

METHOD OF PRODUCING A EUGLENA LYSATE

A method for producing a lysate includes growing a biomass from genus organisms, dewatering the grown biomass, lysing the biomass, and drying the lysed biomass to form a lysate. 1Euglena. A method for producing a lysate , comprising:{'i': 'Euglena', 'growing a biomass from genus organisms;'}dewatering the grown biomass;lysing the biomass; and{'i': 'Euglena', 'drying the lysed biomass to form a lysate.'}2Euglena. The method according to comprising adding a metal to the lysate.3. The method according to wherein the dewatering comprises centrifuging or gravity decanting the biomass.4. The method according to wherein the centrifuging is selected from the group consisting of decanter claim 3 , stacked-disk claim 3 , conical plate claim 3 , pusher claim 3 , and peeler centrifuging.5. The method according to wherein the lysing is selected from the group consisting of mechanical claim 1 , pH and temperature driven.6. The method according to wherein the mechanical lysing comprises homogenizing or bead milling.7. The method according to comprising homogenizing the biomass at a pressure greater than 500 barg.8. The method according to comprising homogenizing the biomass at a pressure range of 500 to 1 claim 7 ,900 barg.9. The method according to comprising homogenizing the biomass at a pressure range of 750 to 1 claim 8 ,000 barg.10. The method according to comprising lysing the biomass at a pH greater than 7.0 and at a temperature greater than 5 degrees centigrade.11. The method according to further comprising treating the biomass with a base and lysing the biomass at a pH greater than 9.0 and at a temperature greater than 45 degrees centigrade.12. The method according to further comprising treating the biomass with a base and lysing the biomass at a pH between 9.0 to 12.5 at a temperature between 45 to 100 degrees centigrade.13. The method according to wherein the drying of the lysed biomass is selected from the group consisting of spray drying claim 1 , ribbon drying claim ...

Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same

The present invention relates to compositions comprising at least about 8% β-glucans and/or at least about 8% α-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising β-glucans and/or α-fucans. 1. A method of treating animals or humans comprising:feeding the animals or humans a composition comprising at least one of:at least 8% w/w partially hydrolysed β-glucans, and/orat least 8% w/w partially hydrolysed α-fucans, in an effective amount to at least one of:{'i': E. coli', 'Salmonella, 'increase growth of beneficial microbes and reduced levels of harmful microbes selected from or in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, or (6) reduce gut infection and inflammation.'}2. The method of claim 1 , wherein the β-glucans comprise at least 8% w/w.3. The method of claim 1 , wherein the α-fucans comprise at least 8% w/w.4. The method of claim 1 , wherein the β-glucans comprise β-(1 claim 1 , 3)(1 claim 1 , 6)-glucans.5. The method of claim 1 , wherein the β-glucans or the α-fucans are derived from a seaweed.6. The method of claim 1 , wherein the β-glucans comprise laminarin.7. The method of claim 1 , wherein the α-fucans comprise fucoidan.8Ascophyllum, Laminaria. The method of claim 8 , wherein the seaweed is selected from Laminariaceae claim 8 , Fucaceae and Gigartinaceae claim 8 , claim 8 , Durvillea claim 8 , Macrocystis claim 8 , Chondrus claim 8 , Ecklonia or any combinations thereof.9. The method of claim 1 , further comprising mannitol claim 1 , lactose or combinations thereof.10. The method of claim 1 , wherein the β-glucans or α-fucans are derived from seaweed by acid-extraction.11. The method of claim 1 , wherein an acid extraction for hydrolysis uses one or more acids selected from ...

COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-KB

The present invention discloses a composition and method for effecting various cytokines and NF-κB by administering an effective amount of a phyto-percolate composition to an individual. In various exemplary embodiments, the composition is claimed to be useful for the effective treatment of inflammation, cancer, and/or various infections including HIV by regulation of various interleukins, such as IL-10 and IL-2, and of transcription factors including NF-κB. 1. A method of treating inflammation in a subject in need thereof; the method comprising administering an effective amount of phyto-percolate derived from culturing microorganisms of ATCC Deposit #PTA-5863 wherein the inflammation is treated by the phyto-percolate up regulating anti-inflammatory cytokines while down regulating pro-inflammatory cytokines.2. The method of claim 1 , wherein the anti-inflammatory cytokines comprise IL-10 and the inflammatory cytokines comprise IL-2.3. The method of claim 1 , wherein the inflammatory cytokines comprise TNF-α.4. The method of claim 1 , wherein the inflammatory cytokines comprise IFN-γ.5. The method of claim 1 , wherein the anti-inflammatory cytokines comprise IL-10 and the inflammatory cytokines comprise IL-2 claim 1 , TNF-α claim 1 , and IFN-γ.6. The method of claim 1 , wherein the phyto-percolate affects the expression of cytokines on a cellular level.7. The method of claim 1 , wherein the phyto-percolate further affects the activation of NF-κB.8. A method of affecting NF-κB in a subject in need thereof; said method comprising administering an effective amount of phyto-percolate derived from culturing microorganisms of ATCC Deposit #PTA-5863 to reduce the overall amount of NF-κB.9. The method of claim 8 , wherein the affecting of NF-κB occurs by decreasing expression claim 8 , activation or the DNA-binding activity of NF-κB.10. The method of claim 8 , wherein the affecting of NF-κB reduces inflammation.11. The method of claim 8 , wherein the affecting of NF-κB ...

Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same

The present invention relates to compositions comprising at least about 8% β-glucans and/or at least about 8% α-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising β-glucans and/or α-fucans. 1. A method of treating animals or humans comprising:feeding the animals or humans a composition comprising at least one of:at least 8% w/w partially hydrolysed β-glucans, and/or{'i': E. coli', 'Salmonella, 'at least 8% w/w partially hydrolysed α-fucans, in an effective amount to at least one of: increase growth of beneficial microbes and reduced levels of harmful microbes selected from or in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, or (6) reduce gut infection and inflammation.'}2. The method of claim 1 , wherein the β-glucans comprise at least 8% w/w.3. The method of claim 1 , wherein the α-fucans comprise at least 8% w/w.4. The method of claim 1 , wherein the β-glucans comprise β-(1 claim 1 , 3)(1 claim 1 , 6)-glucans.5. The method of claim 1 , wherein the β-glucans or the α-fucans are derived from a seaweed.6. The method of claim 1 , wherein the β-glucans comprise laminarin.7. The method of claim 1 , wherein the α-fucans comprise fucoidan.8Laminariaceae, FucaceaeGigartinaceae, Ascophyllum, Laminaria, Durvillea, Macrocystis, Chondrus, Ecklonia. The method of claim 8 , wherein the seaweed is selected from and or any combinations thereof.9. The method of claim 1 , further comprising mannitol claim 1 , lactose or combinations thereof.10. The method of claim 1 , wherein the β-glucans or α-fucans are derived from seaweed by acid-extraction.11. The method of claim 1 , wherein an acid extraction for hydrolysis uses one or more acids selected from lactic acid claim 1 , hydrochloric acid claim 1 , sulfuric ...

Method for mouth mucosa chronic injuries treatment

FIELD: medicine. SUBSTANCE: traumatizing agent is removed. Oral baths with focus powder are carried out for 5-7 days. In addition, Natalgin is received, 2 capsules 2 times a day for 1 month. EFFECT: use of the invention allows to reduce healing time and improve the effectiveness of oral mucosa traumatic lesions treatment. 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 623 053 C1 (51) МПК A61K 36/02 (2006.01) A61K 36/03 (2006.01) A61K 47/36 (2006.01) A61P 1/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ФОРМУЛА (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ 2016124088, 16.06.2016 (24) Дата начала отсчета срока действия патента: 16.06.2016 Дата регистрации: (73) Патентообладатель(и): Кузнецова Надежда Сергеевна (RU) (45) Опубликовано: 21.06.2017 Бюл. № 18 (56) Список документов, цитированных в отчете о поиске: Травма слизистой оболочки рта. Адрес для переписки: 450008, г. Уфа, ул. Ленина, 3, БАШГОСМЕДУНИВЕРСИТЕТ, Патентный отдел 25.05.2016, [найдено 07.04.2017], [найдено в Интернет]: http://www.pitermed.com/ simptomy-bolezni/?cat=18&word=65705;. RU 2577240 C1, 10.03.2016. RU 2506089 C1, 10.02.2014. RU 2158125 C1, 27.10.2000. RU 2275206 C2, 27.04.2006. WO 2012080622 A1, 21.06.2012. 2 6 2 3 0 5 3 Приоритет(ы): (22) Дата подачи заявки: 16.06.2016 R U 21.06.2017 (72) Автор(ы): Жаркова Инна Васильевна (RU), Кабирова Миляуша Фаузиевна (RU), Кузнецова Надежда Сергеевна (RU), Герасимова Лариса Павловна (RU), Усманова Ирина Николаевна (RU) 2 6 2 3 0 5 3 R U (57) Формула изобретения Способ лечения хронических травм слизистой оболочки рта, включающий устранение травмирующего агента, медикаментозную обработку рта, отличающийся тем, что в качестве медикаментозной обработки проводят ротовые ванночки с порошком фукуса в течение 5-7 дней и дополнительно вводят внутрь Натальгин по 2 капсулы 2 раза в день курсом 1 месяц. Стр.: 1 C 1 C 1 (54) СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКИХ ТРАВМ СЛИЗИСТОЙ ОБОЛОЧКИ РТА

Foods or drinks

본 발명은 푸코이단 함유물에서 유도된 푸코이단을 함유, 첨가 및/또는 희석하여 이루어지는 식품 또는 음료, 푸코이단 함유물에서 유도된, 알긴류가 감소 또는 제거된 푸코이단을 함유하는 식품 또는 음료, 세포소멸 유발성을 갖는 푸코이단을 함유하는 세포소멸(apoptosis) 유발성 식품 또는 음료를 제공하는 것을 목적으로 한다.

Feed formulations containing docosahexaenoic acid

The disclosure relates to an animal feed or feed ingredient containing from about 0.01% to 1.0% DHA, wherein all, or substantially all of the DHA comes from material that is of non-animal origin and the use of microbially-derived DHA at these low levels provides sufficient DHA for the optimal neurological development of the animal.

Composition containing Dieckol for treating and preventing neurodegenerative disease

본 발명은 디에콜(Dieckol) 화합물을 유효성분으로 함유하는 퇴행성 신경질환 예방 및 치료용 조성물에 관한 것으로, 보다 구체적으로는, 지질다당류(lipopolysaccharide: LPS)에 의하여 활성화된 미세아교세포(microglia)에 있어서 활성산소종(reactive oxygen species:ROS)의 생성 및 NF-κB의 활성화를 억제하는, 갈조류 유래의 디에콜(Dieckol) 화합물의 용도에 관한 것이다. 상기 디에콜 화합물은 퇴행성 신경질환에 대한 치료 및 예방에 유용하게 사용될 수 있다. The present invention relates to a composition for the prevention and treatment of degenerative neurological diseases containing a Dieckol compound as an active ingredient, and more specifically, to microglia activated by lipopolysaccharide (LPS). The present invention relates to the use of a Dieckol compound derived from brown algae, which inhibits the production of reactive oxygen species (ROS) and the activation of NF-κB. The diecol compound may be usefully used for the treatment and prevention of neurodegenerative diseases. 에클로니아 카바, 디에콜(Dieckol), NF-κB, 퇴행성 신경질환 Eclonia Caba, Dieckol, NF-κB, Degenerative Neuropathy

Pharmacological composition for treatment of chronic tonsillitis, possessing antimicrobial properties

FIELD: medicine, pharmaceutics. SUBSTANCE: invention relates to pharmaceutical industry, namely to composition for treatment of chronic tonsillitis. Composition contains yellow wax, juniper oil, Fitolon oil and 0.05% chlorhexidine solution with the specified ratio of components. EFFECT: claimed composition is effective for treatment of chronic tonsillitis, provides prolonged action of active components, included into its composition; antibacterial, reparative, immunomodulatory effect and long-term elimination of halitosis are achieved. 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (51) МПК A61K 36/02 A61K 36/14 A61K 36/15 A61P 11/04 (11) (13) 2 611 372 C1 (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ФОРМУЛА (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ 2015156624, 28.12.2015 (24) Дата начала отсчета срока действия патента: 28.12.2015 Дата регистрации: Приоритет(ы): (22) Дата подачи заявки: 28.12.2015 (45) Опубликовано: 21.02.2017 Бюл. № 6 2 6 1 1 3 7 2 C 1 (56) Список документов, цитированных в отчете о поиске: И.А. РЕУЦКИЙ. Лечение медом и другими продуктами пчеловодства. Рекомендации для врачей и пациентов. М.: Эксмо, 2007. RU 2220736 С1, 10.01.2004. Фитолон для вашего здоровья и долголетия //Нелекарственная медицина. Научно-практический журнал, 2009. (54) ФАРМАКОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКИХ ТОНЗИЛЛИТОВ, ОБЛАДАЮЩАЯ АНТИМИКРОБНЫМИ СВОЙСТВАМИ (57) Формула изобретения Фармакологическая композиция для лечения хронических тонзиллитов, обладающая антимикробными свойствами, содержащая желтый воск, отличающаяся тем, что она дополнительно содержит масло можжевеловое, масло Фитолон и 0,05% раствор хлоргексидина при следующем соотношении компонентов, мас. %: Масло Фитолон 0,9-1,1 Масло можжевеловое 0,9-1,1 Хлоргексидин 0,05% раствор 48,0-50,0 Желтый воск 48,0-50,0 Стр.: 1 C 1 R U (73) Патентообладатель(и): государственное бюджетное образовательное учреждение высшего профессионального образования "Первый ...

Methods and Compositions Related to Antiviral Therapy Using Algae and Cyanobacteria

Disclosed are methods and compositions related to treating and preventing viral infection.

Compounds and methods for affecting cytokines

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-α, lactoferrin, IFN-γ, IL-1β, serum amyloid-A (SAA), IL-6 and/or β-defensin associated with infection or an immune response generally.

Composition for controlling blood sugar

The present invention is related to a composition for controlling blood sugar, which includes effective amount of blue algae and mulberry leaves. It can control blood sugar by means of the blue algae helping blood sugar metabolism and mulberry leaves blocking sugar decomposition and entering into blood. The present invention also discloses an oral prophylactic agent containing the composition.

Detoxifying and / or regenerating agent

Beschrieben wird ein Entschlackungs- und/oder Regenerationsmittel für die externe Anwendung sowie ein Verfahren zur Entschlackung, wobei das Entschlackungsmittel ein Minaralpulver aus Tonerde, Meersalz, Mineralien, Algen und ätherischen Ölen enthält, die in ein auf der Körperoberfläche zu tragendes Bekleidungsstück als Aufschwemmung eingebracht werden. Described is a detoxifying and / or regenerating agent for external use as well as a method for detoxifying, the detoxifying agent containing a mineral powder of alumina, sea salt, minerals, algae and essential oils which are introduced as a suspension in a piece of clothing to be worn on the body surface ,

Extracting method for algal polyphenols

一种海藻多酚的提取方法，以蛋白核小球藻、裸藻、盐藻三种藻类为原料，以乙醇为溶剂，采用微波联合提取三种藻类的多酚。本发明的一种海藻多酚的提取方法，（1）工艺简单实用，工艺流程安全；（2）不需大型设备仪器，生产成本低；（3）实现同时对蛋白核小球藻、裸藻、盐藻三种原料海藻多酚的提取，并且适用于大量样品的处理。

Iodine-enriched extract preparation from algae by washing, drying, dissolving, concentrating and removing toxic metals, used in slow iodine release patches for stimulating thyroid function and lipolysis

L'invention concerne un procédé de préparation d'un extrait algal enrichi en iode, selon lequel : a) on procède au lavage d'algues fraîches à l'aide d'eau de mer et éventuellement, à l'aide d'eau douce;b) on réalise le séchage des algues lavées jusqu'à obtention d'une masse constante, puis on procède à leur broyage; c) on met en solution aqueuse la poudre obtenue à l'étape b); d) on récupère la phase aqueuse contenant l'iode;e) on procède à la concentration de ladite phase pour obtenir un extrait algal; f) on réalise l'élimination des métaux toxiques sur le plan pharmaceutique, notamment des composés à base de cadmium, de plomb et d'arsenic.L'invention se rapporte également à un procédé de fabrication d'un timbre cutané à libération graduelle d'iode, ainsi qu'aux produits obtenus conformément aux procédés.

Application of fucoidan to preparing products for preventing and/or treating lower limb peripheral artery vascular diseases

本发明公开了褐藻多糖硫酸酯在制备预防和/或治疗下肢外周动脉血管病的产品中的应用。本发明褐藻多糖硫酸酯应用于制备预防和/或治疗下肢外周动脉血管病的产品中。低分子量褐藻多糖硫酸酯(LMWF)来源于天然存在的海带之中，其易得、安全；能对下肢外周血管病有一定改善作用。含低分子量褐藻多糖硫酸酯的产品，口服可吸收，副作用少等优点，对防治下肢外周动脉血管病具有潜在的应用意义。

A method of cultivating haematococcus algae using deep sea water and a method of producing astaxanthin

본 발명은 해마토코쿠스 조류(Haematococcus algae)를 배양하는 방법과 이를 이용한 아스타크산틴(Astaxanthin)을 생산하는 방법에 관한 것으로, 더욱 상세하게는 해수면에서 수심 200m보다 깊은 해저심층의 해양 심층수를 이용하여 해마토코쿠스 조류를 배양하는 방법과 이 해마토코쿠스 조류로부터 아스타크산틴을 생산하는 방법에 관한 것이다. 이를 위하여 본 발명은 해마토코쿠스 조류를 배양하여, 이 해마토코쿠스 조류로부터 아스타크산틴을 생산하는데 있어서, 해수면에서 수심 200m보다 깊은 해저심층의 해양 심층수를 취수하여 NaCl을 제거한 미네랄 수를 생산하는 단계, 상기 미네랄 수를 이용하여 배양액을 만드는 단계, 상기 배양액을 이용하여 해마토코쿠스 조류를 배양하는 단계, 상기 해마토코쿠스 조류로부터 아스타크산틴을 생산하는 단계로 이루어진 것에 특징이 있다. 해양 심층수, 해마토코쿠스 조류(Haematococcus algae), 미네랄 수, 아스타크산틴(Astaxanthin)

PURIFICATION AND / OR REGENERATION AGENTS

Feed formulations containing docosahexaenoic acid

The disclosure relates to an animal feed or feed ingredient containing from about 0.01% to 1.0% DHA, wherein all, or substantially all of the DHA comes from material that is of non-animal origin and the use of microbially-derived DHA at these low levels provides sufficient DHA for the optimal neurological development of the animal.

Seaweed compound for auxiliary treatment of type 2 diabetes and preparation method thereof

本发明提供了一种辅助治疗2型糖尿病的海藻复合物及其制备方法，具体以泡叶藻、马尾藻、浒苔、墨角藻、裙带菜、麒麟菜的提取物为海藻复合剂，辅助添加桦褐孔菌和桑黄提取物。本发明提供的复合物是海源与陆源药食两用材料的有效提取物复配制备而成。经药效学验证，该海藻复合物能显著降低2型糖尿病空腹血糖值，预防和辅助治疗2型糖尿病，可制成胶囊剂、颗粒剂、片剂、丸剂或溶液剂。

Purifying and/or regenerating agent

The invention relates to a purifying and/or regenerating agent for external use and to a purifying method. The purifying agent contains a mineral powder of alumina, sea salt, minerals, algae and ethereal oils that are applied in the form of a slurry on a garment to be worn on the body surface.

Composition containing dieckol for treating and preventing neurodegenerative disease

본 발명은 디에콜(Dieckol) 화합물을 유효성분으로 함유하는 퇴행성 신경질환 예방 및 치료용 조성물에 관한 것으로, 보다 구체적으로는, 지질다당류(lipopolysaccharide: LPS)에 의하여 활성화된 미세아교세포(microglia)에 있어서 활성산소종(reactive oxygen species:ROS)의 생성 및 NF-κB의 활성화를 억제하는, 갈조류 유래의 디에콜(Dieckol) 화합물의 용도에 관한 것이다. 상기 디에콜 화합물은 퇴행성 신경질환에 대한 치료 및 예방에 유용하게 사용될 수 있다. 에클로니아 카바, 디에콜(Dieckol), NF-κB, 퇴행성 신경질환

Antalgic mat for magnetic therapy

Una alfombrilla para aliviar el dolor, para magnetoterapia de un usuario, teniendo la alfombrilla extremos longitudinalmente opuestos denominados como lado de los pies y lado de la cabeza, comprendiendo la alfombrilla al menos: a. un primer tejido compuesto por al menos una fibra cerámica biocompatible configurada para generar un efecto analgésico reflejando las ondas FIR emitidas por el usuario; b. dos pares de bandas magnéticas para una magnetización norte-sur ubicadas en los extremos de dicha alfombrilla, comprendiendo dichos dos pares de bandas magnéticas dos bandas dispuestas en el lado de los pies y dos bandas dispuestas en el lado de la cabeza; c. bandas magnéticas centrales, ubicadas en el centro con respecto a la dirección longitudinal de la alfombrilla, preferiblemente interpuestas entre las bandas magnéticas en el lado de los pies y las bandas magnéticas en el lado de la cabeza; estando caracterizada la alfombrilla por comprender, además: d. un tejido inferior, configurado para: i. conectar la alfombrilla a un generador configurado para generar ondas electromagnéticas pulsadas de alta y/o de baja frecuencia y ii. generar un campo de radiofrecuencia monopolar para ser emitido regularmente de manera homogénea hacia el usuario, y e. uno o más hilos sintéticos, seleccionados de entre una fibra de cobre, una fibra de carbono y/o una fibra tratada con iones de plata denominada fibra de plata. A pain relieving mat for magnetic therapy of a user, the mat having longitudinally opposite ends referred to as foot side and head side, the mat comprising at least: a. a first fabric composed of at least one biocompatible ceramic fiber configured to generate an analgesic effect by reflecting the FIR waves emitted by the user; b. two pairs of magnetic bands for north-south magnetization located at the ends of said mat, said two pairs of magnetic bands comprising two bands arranged on the foot side and two bands arranged on the head side; c. central magnetic stripes, ...

Composition and use of phyto-percolate for treatment of disease

This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The invention further relates to the use of the phyto-percolate in a variety of disease states. The phyto-percolate is believed to contain an activity that induces the reduction of soluble and insoluble fibrin. Further, the phyto-percolate is believed to reduce oxidative stress in the body.

PROCESS FOR TRANSFORMATION OF CONCENTRATED BIOMASS WITH A VIEW TO OBTAINING A FOOD PREPARATION.

PROCÉDÉ DE TRANSFORMATION D’UNE BIOMASSE CONCENTRÉE EN VUE D’OBTENIR UNE PRÉPARATION ALIMENTAIRE. L’invention vise un procédé de transformation d’une biomasse de culture cellulaire de microalgue, ou de cyanobactérie, pour obtenir une préparation alimentaire, qui comporte les étapes suivantes :- rinçage de la biomasse avec de l’eau stérilisée et- refroidissement de la biomasse rincée à moins de 9°C en moins de 40 minutes. L’invention vise également une préparation alimentaire obtenue par un tel procédé. Figure pour l’abrégé : figure 8 PROCESS FOR TRANSFORMATION OF CONCENTRATED BIOMASS WITH A VIEW TO OBTAINING A FOOD PREPARATION. The invention relates to a process for transforming a biomass from microalgae cell culture, or from cyanobacteria, to obtain a food preparation, which comprises the following steps: - rinsing of the biomass with sterilized water and - cooling of the biomass rinsed at less than 9 ° C in less than 40 minutes. The invention also relates to a food preparation obtained by such a process. Figure for the abstract: figure 8

Improvements relating to seaweed-derived preparations

A gel comprising a mixture of grains of seaweed of the species Lithothamnion calcareum or Phymatolithon calcareum together with grains of a seaweed of the brown algae branch, is used for the manufacture of a medicament for treatment of conditions produced by herpes simplex viruses types 1 and 2. The invention also provides a method of treating conditions produced by herpes simplex virus, comprising topical application of the gel.

Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them

In alternative embodiments, provided herein are transcription/ translation (TX-TL) systems and methods of using them for use as rapid prototyping platforms for the synthesis, modification and identification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites, from biosynthetic gene cluster pipelines. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the combinatorial biosynthesis of natural products (NPs), natural product analogs (NPAs) and secondary metabolites. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the rapid prototyping of complex biosynthetic pathways as a way to rapidly assess combinatorial and biosynthetic designs before moving to cellular hosts. In alternative embodiments, these exemplary TX-TL systems are multiplexed for high-throughput (HT) automation and for prototyping engineered platforms for the synthesis or modification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites analogs.

Protein extract of marine macroalgae, method for its production and uses

Preparing protein extract from macro algae, comprises (a) providing crushed algae raw material, (b) absorbing the crushed algae raw material in an aqueous extraction buffer, which is adjusted with a pH of 3-10, (c) extracting the material at 0-10[deg] C, and (d) centrifuging the extraction mixture at 5-30000 g, and recovering the supernatant. An independent claim is also included for the protein extract made of macro algae, preferably brown-, red- or green algae, obtained by the above method, exhibiting a proliferation-influencing effect on individual cells, preferably heterotrophic eukaryotic cells.

Process for the production of cell division promoting substances from freshwater algae

Feed formulations containing docosahexaenoic acid

The disclosure relates to an animal feed or feed ingredient containing from about 0.01% to 1.0% DHA, wherein all, or substantially all of the DHA comes from material that is of non-animal origin and the use of microbially-derived DHA at these low levels provides sufficient DHA for the optimal neurological development of the animal.

High-efficiency extraction method of algae polyphenol

本发明涉及一种高效的藻类多酚提取方法，本方法提取的藻类多酚既有较高的总酚含量，又保留了良好的抗氧化活性。海藻类包含裙带菜孢子叶、紫菜、羊栖藻、海带、泡叶藻等藻类，本制作以其中的裙带菜孢子叶为例。其提取方法及步骤是：1)干裙带菜孢子叶的挑选、2)烘干打粉、3)泡发、超声4)酶解、5)高温密闭提取、6)离心、7)旋蒸回收、8)冻干保存、9)化学法检测所得酚的含量及抗氧化活性。本发明的有益效果：充分提取海藻中的多酚，在不破坏其抗氧化活性的条件下尽可能提高海藻的总酚含量。充分利用藻类，让藻类中营养物质更加容易被人体吸收，多酚生物活性良好，原料丰富，成本低廉。

Composition comprising Oscillatoria agardhii extracts for prevention and treatment of cancer and method of preparing the extracts

본 발명은 오실레토리아 아가르디히( Oscillatoria agardhii ) 추출물을 포함하는 암의 치료 및 예방용 조성물과 상기 추출물의 제조방법에 관한 것으로서, 더욱 상세하게는 오실레토리아 아가르디히 균주의 알콜 또는 디클로로메탄 추출물과 이의 분획물이 다양한 암 세포에 대한 저해 효과와 종양 억제 활성을 가진다는 것을 밝힘으로써 암의 치료 및 예방을 위한 약제 또는 식품의 유효 성분으로 활용될 수 있는, 오실레토리아 아가르디히 추출물을 포함하는 암의 치료 및 예방용 조성물과 오실레토리아 아가르디히로부터 효과적으로 상기 추출물을 얻을 수 있는 방법에 관한 것이다. The present invention relates to a composition for the treatment and prevention of cancer, comprising the Oscillatoria agardhii extract, and to a method of preparing the extract, and more particularly, to an alcohol or dichloromethane of an oscillatoria agardihi strain. Includes Oscilleria agardihi extract, which can be used as an active ingredient in pharmaceuticals or foods for the treatment and prevention of cancer by revealing that the extract and fractions thereof have inhibitory effects and tumor suppression activity against various cancer cells. The present invention relates to a composition for treating and preventing cancer and a method for effectively obtaining the extract from an oscillatoria agardi. 해양 미생물, 남조류, 오실레토리아 아가르디히, 저급 알콜, 항암제, 종양 억제 Marine microorganisms, cyanobacteria, osiletoria agardich, lower alcohols, anticancer agents, tumor suppression

Composition for Treating or Preventing Dementia Comprising Nannochloropsis oceanica Extracts As Active Ingredient

본 발명은 난노클로롭시스 오세아니카(Nannochloropsis oceanica) 추출물을 유효성분으로 포함하는 조성물에 관한 것으로, 상기 추출물은 마우스 모델의 LPS로 유도된 기억장애를 개선시키고, 뇌신경세포를 구성하는 성상세포 및 미세아교세포 BV-2에서 LPS에 의해 유도되는 iNOS(inducible nitric oxide synthase)와 COX-2(cyclooxygenase-2) 발현 및 NO(nitric oxide)의 생성을 억제하며, LPS에 의해 유도되는 Aβ의 생성, NF-κB 활성 및 β-세크리타아제의 활성을 억제하고, LPS에 의해 유도되는 산화적 스트레스를 감소시키므로 치매의 예방 또는 치료용 조성물로 유용하게 사용될 수 있다.

A kind of application of fucoidin in the cells of PC 12 or the cell active inhibitors of MKN 45 is prepared

本发明公开了一种岩藻多糖在制备PC‑12细胞或MKN‑45细胞活性抑制剂中的应用，采用本发明的制备方法制取岩藻多糖作为抗肿瘤(PC‑12，MKN‑45)及抗氧化剂，具备纯度高(71％‑92％)，操作简单，反应条件易于控制、工艺成本低等特点。本发明的制备方法制取分离得到的岩藻多糖(FCSP，FCSP‑1，FCSP‑2，FCSP‑3)，其抗肿瘤(PC‑12，MKN‑45)抑制率要高于市售岩藻多糖(纯度80％，来自于陕西天然原料汇)对PC‑12，MKN‑45的抑制率。采用本发明制备的岩藻多糖作为抗肿瘤(PC‑12，MKN‑45)及抗氧化剂，也可以用于食品添加剂产品可制成粉剂、水剂、针剂等剂型。

Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them

In alternative embodiments, provided herein are transcription/translation (TX-TL) systems and methods of using them for use as rapid prototyping platforms for the synthesis, modification and identification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites, from biosynthetic gene cluster pipelines. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the combinatorial biosynthesis of natural products (NPs), natural product analogs (NPAs) and secondary metabolites. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the rapid prototyping of complex biosynthetic pathways as a way to rapidly assess combinatorial and biosynthetic designs before moving to cellular hosts. In alternative embodiments, these exemplary TX-TL systems are multiplexed for high-throughput (HT) automation and for prototyping engineered platforms for the synthesis or modification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites analogs.

클로렐라를 함유하는 간기능 장해 개선제

건강 보조식품으로 알려져 있는 클로렐라를 함유하여 카드뮴에 의해 유발된 간 경변과 같은 간 기능 장해를 억제할 수 있는 개선제에 관한 것이다.

Method for the Stimulation of Human Immune Cells

Provided herein is a substance for use in a therapeutic method for stimulating cells in the human immune system, a method for producing this substance, and a method of use of the substance for stimulating cells of the human immune system in treating various diseases involving immune system disorders.

남극 해조류의 추출물을 유효성분으로 포함하는 세포장벽 보호 기능 및 라디칼 소거활성을 갖는 조성물

본 발명은 남극 해조류의 추출물을 유효성분으로 포함하는 세포장벽 보호 기능 및 라디칼 소거활성을 갖는 조성물에 관한 것으로서, 더욱 상세하게는 사람의 장상피세포주를 이용하여 남극 해조류 추출물의 특이적 영향 분석을 통해 세포장벽의 기능을 조절하고, 라디칼 소거활성이 우수한 조성물을 제공하는 것에 관한 것이다. 본 발명에 따른 남극 해조류의 추출물을 유효성분으로 포함하는 조성물은 세포장벽을 보호하는 효과가 있고, 남극 해조류 추출물 자체의 H 2 O 2 , OH, ONOO- 라디칼 소거활성을 발휘하는 해조류 조성물을 제시할 수 있다.

오실레토리아 아가르디히 추출물을 포함하는 암의 치료 및예방용 조성물과 상기 추출물의 제조방법

본 발명은 오실레토리아 아가르디히( Oscillatoria agardhii ) 추출물을 포함하는 암의 치료 및 예방용 조성물과 상기 추출물의 제조방법에 관한 것으로서, 더욱 상세하게는 오실레토리아 아가르디히 균주의 알콜 또는 디클로로메탄 추출물과 이의 분획물이 다양한 암 세포에 대한 저해 효과와 종양 억제 활성을 가진다는 것을 밝힘으로써 암의 치료 및 예방을 위한 약제 또는 식품의 유효 성분으로 활용될 수 있는, 오실레토리아 아가르디히 추출물을 포함하는 암의 치료 및 예방용 조성물과 오실레토리아 아가르디히로부터 효과적으로 상기 추출물을 얻을 수 있는 방법에 관한 것이다. 해양 미생물, 남조류, 오실레토리아 아가르디히, 저급 알콜, 항암제, 종양 억제

一种藻类多酚高效提取方法

本发明涉及一种高效的藻类多酚提取方法，本方法提取的藻类多酚既有较高的总酚含量，又保留了良好的抗氧化活性。海藻类包含裙带菜孢子叶、紫菜、羊栖藻、海带、泡叶藻等藻类，本制作以其中的裙带菜孢子叶为例。其提取方法及步骤是：1)干裙带菜孢子叶的挑选、2)烘干打粉、3)泡发、超声4)酶解、5)高温密闭提取、6)离心、7)旋蒸回收、8)冻干保存、9)化学法检测所得酚的含量及抗氧化活性。本发明的有益效果：充分提取海藻中的多酚，在不破坏其抗氧化活性的条件下尽可能提高海藻的总酚含量。充分利用藻类，让藻类中营养物质更加容易被人体吸收，多酚生物活性良好，原料丰富，成本低廉。

미세조류 나비쿨라 인세르타의 가수분해물 및 이를 포함하는 항산화 조성물

본 발명은 미세조류 가수분해물 및 이 가수분해물을 포함하는 항산화 조성물에 관한 것으로, 더욱 상세하게는 미세조류 나비쿨라 인세르타( Navicula incerta )의 최적 성장 조건 및 이의 가수분해물 및 이를 포함하는 항산화 조성물에 관한 것이다.

Method of treating bacterial contamination in a microalgae culture with ph shock

Methods of treating contamination, particularly bacterial contamination, in an open culture of microalgae with organic carbon are described herein. The methods comprise reducing the pH of a culture for a period of time and then raising the pH of the culture, wherein the culture comprises the presence of a first acid and the culture is contacted with a second acid to reduce the culture pH from a first pH value to a second pH value. The culture is maintained at the second pH value for at least 5 minutes before the culture pH is raised from the second pH value by contact with a base.

클로렐라를 함유하는 간기능 장해 개선제

건강 보조식품으로 알려져 있는 클로렐라를 함유하여 카드뮴에 의해 유발된 간 경변과 같은 간 기능 장해를 억제할 수 있는 개선제에 관한 것이다.

[UNK]

Procedimiento para la extracción de carotenoides utilizando fases líquidas nanoestructuradas

La presente invención se refiere a un procedimiento para la obtención y enriquecimiento de carotenoides a partir de biomasa, basado en el uso de fases líquidas nanoestructuradas, y al uso de los carotenoides así obtenidos como aditivos alimentarios y en la industria farmacéutica.

一种大型海藻活性素的生物提取方法

本发明公开了一种大型海藻活性素的生物提取方法，以解决现有技术活性成分提取方法易破坏有效成分，且提取剂用量大、提取效率低的问题。大型海藻活性素的仿生提取方法，包括以下步骤：1）配制仿生胃液；2）配制仿生肠液；3)将海藻干燥粉碎并50-80目筛过筛，得较均匀的海藻粉末；4)向海藻粉末加入仿生胃液，发酵30-50h；5)发酵后的药物采用孔径为0.005-0.01um的超滤膜过滤；6)向超滤透过液中加入仿生肠液，将PH调为6.5-7.5。本发明方法提取的大型海藻活性素，有效成分提取充分，吸收速度快、有效组分的结构或组成不变。本发明是天然药物应用领域的重要突破。

Extract with anti-inflammatory effect

The present invention relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria. The invention further relates to compositions comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS. The invention further relates to pharmaceutical compositions comprising the anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient. The invention further relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof or a pharmaceutical composition comprising an anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient for use as a medicament, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria. The invention further relates to compositions comprising an anti- inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria.

Paramylon-based resin, molding material, molded body, and method for producing paramylon-based resin

A paramylon-based resin having a weight-average molecular weight of paramylon in a range of 70000 to 140000, and formed by substituting hydrogen atoms of hydroxy groups of a paramylon with a long-chain component being a linear saturated aliphatic acyl group having 14 or more carbon atoms and a short-chain component being an acyl group (acetyl group or/and propionyl group) having 2 or 3 carbon atoms, wherein a degree of substitution with the long-chain component (DSLo) and a degree of substitution with the short-chain component (DSSh) satisfy the following conditional expressions (1) and (2), Izod impact strength is 5.0 kJ/m2 or more, and an MFR (melt flow rate at 210° C. and under a load of 5 kg) is 2 g/10 min or more. To provide a paramylon-based resin excellent in mechanical characteristics and thermoplasticity. 2.2≤DSLo+DSSh≤2.8 (1) 5≤DSSh/DSLo≤25 (2)

자이로디니움 임푸디쿰 ＫＧ03 균주(ＫＣＴＣ10325ＢＰ)에 의하여 생산되는 황함유세포외다당류(ｐ-ＫＧ03)를 함유하는 면역활성용 조성물

본 발명은 자이로디니움 임푸디쿰(Gyrodinium impudicum) KG03 균주(KCTC 10325BP)에 의하여 생산되는 황함유 세포외다당류(sulfated exopolysaccharide) 및 이를 유효성분으로 포함하는 조성물에 관한 것이다. 보다 상세히 설명하면, 본 발명은 in vivo에서 IgG 및 IgM의 생성, NK 세포의 항암세포 독성능, 사이토카인의 생성, 일산화질소의 생성, 및 과산화수소의 생성 등을 증가시킴으로써 우수한 면역활성효과를 나타내는 황함유 세포외다당류(sulfated exopolysaccharide) 및 이를 유효성분으로 포함하는 조성물에 관한 것이다.

케토세로스 그라실리스 유래 푸코잔틴 함유 추출물을 활성성분으로 함유하는 간세포 보호용 조성물 및 이의 생산방법

본 발명은 초임계 이산화탄소와 공용매로 콜로브 오일을 케토세로스 그라실리스가 수용된 반응조에 투입하여 추출된 푸코잔틴 함유 추출물을 활성성분으로 함유하는 것을 특징으로 하는 간세포 보호용 조성물 및 이의 생산방법을 제공한다.

Procedimiento para la extracción de carotenoides utilizando fases líquidas nanoestructuradas

Procedimiento para la extracción de carotenoides utilizando fases líquidas nanoestructuradas. La presente invención se refiere a un procedimiento para la obtención y enriquecimiento de carotenoides a partir de biomasa, basado en el uso de fases líquidas nanoestructuradas, y al uso de los carotenoides así obtenidos como aditivos alimentarios y en la industria farmacéutica.

Procedimiento para la extracción de carotenoides utilizando fases líquidas nanoestructuradas

一种海藻硫酸多糖的应用

本发明涉及药物技术领域，具体涉及一种海藻硫酸多糖的应用。所述海藻硫酸多糖在防治微波辐射方面的应用。通过一系列实验研究证明，海藻硫酸多糖在防治微波辐射方面具有很好地效果。

Diatom device

Diatom devices are disclosed including devices for biocompatible implantation. The diatom structures are useful for providing living cells and tissues as well as biologically active molecules to subjects.

パラミロン系樹脂の製造方法

Extract with anti-inflammatory effect

The present invention relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria . The invention further relates to compositions comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS. The invention further relates to pharmaceutical compositions comprising the anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient. The invention further relates to an anti-inflammatory extract of soil microorganisms or a fraction thereof or a pharmaceutical composition comprising an anti-inflammatory extract of soil microorganisms or a fraction thereof or a composition comprising two or more of Lyso-DGTS, p-Coumaric acid (ester-linked), oleamide, theophylline, or DGTS as an active ingredient for use as a medicament, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria . The invention further relates to compositions comprising an anti- inflammatory extract of soil microorganisms or a fraction thereof, wherein the microorganisms comprise one or more selected from Chlorophyta, Xanthophyceae or Cyanobacteria .

Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them

In alternative embodiments, provided herein are transcription/ translation (TX-TL) systems and methods of using them for use as rapid prototyping platforms for the synthesis, modification and identification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites, from biosynthetic gene cluster pipelines. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the combinatorial biosynthesis of natural products (NPs), natural product analogs (NPAs) and secondary metabolites. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the rapid prototyping of complex biosynthetic pathways as a way to rapidly assess combinatorial and biosynthetic designs before moving to cellular hosts. In alternative embodiments, these exemplary TX-TL systems are multiplexed for high-throughput (HT) automation and for prototyping engineered platforms for the synthesis or modification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites analogs.

Process of treating sea algae and halophytic plants

The process of treating sea algae/halophytes. The sea algae/halophyte in an aqueous solution containing an acid is soaked for a sufficient length of time to substantially reduce the mineral content of the sea algae/halophyte. The initial mineral content is expressed on the basis of the total ash content of the untreated sea algae/halophyte in the dried state. The soak-treated sea algae is separated from the aqueous solution. The separated sea algae/halophyte can be dried to provide a dried sea algae/halophyte product having substantially reduced mineral content and increased nutritional value.

자이로디니움 임푸디쿰 ＫＧ03 균주(ＫＣＴＣ10325ＢＰ)에 의하여 생산되는 황함유세포외다당류(ｐ-ＫＧ03)를 함유하는 면역활성용 조성물

본 발명은 자이로디니움 임푸디쿰(Gyrodinium impudicum) KG03 균주(KCTC 10325BP)에 의하여 생산되는 황함유 세포외다당류(sulfated exopolysaccharide) 및 이를 유효성분으로 포함하는 조성물에 관한 것이다. 보다 상세히 설명하면, 본 발명은 in vivo에서 IgG 및 IgM의 생성, NK 세포의 항암세포 독성능, 사이토카인의 생성, 일산화질소의 생성, 및 과산화수소의 생성 등을 증가시킴으로써 우수한 면역활성효과를 나타내는 황함유 세포외다당류(sulfated exopolysaccharide) 및 이를 유효성분으로 포함하는 조성물에 관한 것이다. 황함유 세포외다당류(sulfated exopolysaccharide) * 해양성미세조류 * 면역강화제 * 자이로디니움 임푸디쿰(Gyrodinium impudicum)

알긴산소다를 주제로 한 위장관질환치료제에 대한 개량 및 그의 제조방법

내용 없음.

Composition and paste for eliminating abnormal conditions in a human affected by chaotic environmental electromagnetism and the manufacturing method thereof

The present disclosure is related to a composition having an effective amount of algae for eliminating abnormal conditions in a human affected by chaotic environmental electromagnetism. Furthermore, the present invention is also related to a paste having an adhesive layer and a non-adhesive layer formed from the composition for eliminating abnormal conditions in a human affected by chaotic environmental electromagnetism as described above. The present invention is also related to methods for manufacturing the paste and the composition as described above. In addition, the present invention is related to a method of eliminating abnormal conditions in a human affected by electromagnetism.

一种高效提取海洋球石藻细胞总脂的方法

本发明公开了一种高效提取海洋球石藻细胞总脂的方法；属于生物制药技术领域；其制备步骤包括：S1：将海洋球石藻粉置于提取溶剂中进行浸提，得到浸提物；S2：将所述浸提物离心，干燥，得到海洋球石藻细胞总脂粗提物；上述醇衍生物由双（7‑氧杂双环[4.1.0]3‑庚甲基）己二酸酯水解开环制得。再将海洋球石藻细胞总脂粗提物纯化，得到海洋球石藻细胞总脂的各成分；提取溶剂包括醇衍生物；本发明方法能够得到提取率较高的海洋球石藻细胞总脂粗提物，且得到的总脂成分中含有较多的C16:1、C18:2、C20:n6、C22:6脂肪酸。

알긴 산소다를 주제로한 위장관질환치료제에 대한 개량 및 그의 제조방법

내용 없음.

一种高效提取海洋球石藻细胞总脂的方法

本发明公开了一种高效提取海洋球石藻细胞总脂的方法；属于生物制药技术领域；其制备步骤包括：S1：将海洋球石藻粉置于提取溶剂中进行浸提，得到浸提物；S2：将所述浸提物离心，干燥，得到海洋球石藻细胞总脂粗提物；上述醇衍生物由双（7‑氧杂双环[4.1.0]3‑庚甲基）己二酸酯水解开环制得。再将海洋球石藻细胞总脂粗提物纯化，得到海洋球石藻细胞总脂的各成分；提取溶剂包括醇衍生物；本发明方法能够得到提取率较高的海洋球石藻细胞总脂粗提物，且得到的总脂成分中含有较多的C16:1、C18:2、C20:n6、C22:6脂肪酸。

一种高效提取海洋球石藻细胞总脂的方法

本发明公开了一种高效提取海洋球石藻细胞总脂的方法；属于生物制药技术领域；其制备步骤包括：S1：将海洋球石藻粉置于提取溶剂中进行浸提，得到浸提物；S2：将所述浸提物离心，干燥，得到海洋球石藻细胞总脂粗提物；上述醇衍生物由双（7‑氧杂双环[4.1.0]3‑庚甲基）己二酸酯水解开环制得。再将海洋球石藻细胞总脂粗提物纯化，得到海洋球石藻细胞总脂的各成分；提取溶剂包括醇衍生物；本发明方法能够得到提取率较高的海洋球石藻细胞总脂粗提物，且得到的总脂成分中含有较多的C16:1、C18:2、C20:n6、C22:6脂肪酸。

Entschlackungs- und/oder regenerationsmittel

一种从微藻中提取生长因子的方法

本发明涉及成分提取技术领域，具体涉及一种从微藻中提取生长因子的方法，包括如下步骤：(1)将微藻粉碎、过筛，得到微藻粉末；(2)将微藻粉末投入35～45℃的EDTA‑2Na水溶液中浸渍，得到微藻泥；(3)对微藻泥进行至少一次冻融处理，然后离心得到上清液和沉淀；(4)取沉淀，与萃取剂一起进行湿法球磨粉碎，沉淀、萃取剂与磨球的质量比为1：1～3：1.5～3，得到萃取液，干燥，得到生长因子。本发明利用冻融和湿法球磨工艺提取微藻中生长因子，方法简单，操作方便，工艺要求低。

一种从微藻中提取生长因子的方法

本发明涉及成分提取技术领域，具体涉及一种从微藻中提取生长因子的方法，包括如下步骤：(1)将微藻粉碎、过筛，得到微藻粉末；(2)将微藻粉末投入35～45℃的EDTA‑2Na水溶液中浸渍，得到微藻泥；(3)对微藻泥进行至少一次冻融处理，然后离心得到上清液和沉淀；(4)取沉淀，与萃取剂一起进行湿法球磨粉碎，沉淀、萃取剂与磨球的质量比为1：1～3：1.5～3，得到萃取液，干燥，得到生长因子。本发明利用冻融和湿法球磨工艺提取微藻中生长因子，方法简单，操作方便，工艺要求低。

一种用于多功能磁疗的止痛垫

一种用于多功能磁疗的止痛垫，由生物陶瓷纤维组织、南北磁化的磁性带、中心磁性带、和下部组织组成，并被配置成能够将该垫连接到用于磁疗的任何发生器设备，以及例如铜纤维、碳纤维、和银纤维的工程纱线。

Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters

The introduction of tools to study, control or expand the inner-workings of algae has been slow to develop. Provided are embodiments of a molecular method based on guanidinium-rich molecular transporters (GR-MoTrs) for bringing molecular cargos into algal cells. The methods of the disclosure have been shown to work in wild-type algae that have an intact cell wall. Developed using Chlamydomonas reinhardtii , this method is also successful with less studied algae, including Neochloris oleoabundans and Scenedesmus dimorphus , thus providing a new and versatile tool for algal research and modification. The method of delivering a cargo compound to an algal cell comprises contacting an algal cell with a guanidinium-rich delivery vehicle comprising a guanidinium-rich molecular transporter (GR-MoTr) linked to a cargo compound desired to be delivered to the algal cell, whereby the guanidinium-rich molecular transporter can traverse the algal cell wall, thereby delivering the cargo compound to the algal cell.

Method of treating bacterial contamination in a microalgae culture with pH shock

Methods of treating contamination, particularly bacterial contamination, in an open culture of microalgae with organic carbon are described herein. The methods comprise reducing the pH of a culture for a period of time and then raising the pH of the culture, wherein the culture comprises the presence of a first acid and the culture is contacted with a second acid to reduce the culture pH from a first pH value to a second pH value. The culture is maintained at the second pH value for at least 5 minutes before the culture pH is raised from the second pH value by contact with a base.